CN117794861A - 生产包含含镁离子材料的粒料的方法 - Google Patents
生产包含含镁离子材料的粒料的方法 Download PDFInfo
- Publication number
- CN117794861A CN117794861A CN202280053423.2A CN202280053423A CN117794861A CN 117794861 A CN117794861 A CN 117794861A CN 202280053423 A CN202280053423 A CN 202280053423A CN 117794861 A CN117794861 A CN 117794861A
- Authority
- CN
- China
- Prior art keywords
- containing material
- acid
- magnesium ion
- magnesium
- bar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 321
- 239000008188 pellet Substances 0.000 title claims abstract description 192
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 title claims abstract description 167
- 229910001425 magnesium ion Inorganic materials 0.000 title claims abstract description 167
- 238000000034 method Methods 0.000 title claims abstract description 95
- 230000008569 process Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 27
- 206010013786 Dry skin Diseases 0.000 claims abstract description 9
- 230000037336 dry skin Effects 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 235000016709 nutrition Nutrition 0.000 claims abstract description 9
- 238000004806 packaging method and process Methods 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 6
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 247
- 239000002245 particle Substances 0.000 claims description 203
- 239000001095 magnesium carbonate Substances 0.000 claims description 145
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 144
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 143
- 239000011777 magnesium Substances 0.000 claims description 78
- -1 gums Polymers 0.000 claims description 75
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 70
- 239000007900 aqueous suspension Substances 0.000 claims description 70
- 239000011148 porous material Substances 0.000 claims description 70
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 52
- 125000004432 carbon atom Chemical group C* 0.000 claims description 49
- 238000001694 spray drying Methods 0.000 claims description 48
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 46
- 239000007884 disintegrant Substances 0.000 claims description 45
- 238000000265 homogenisation Methods 0.000 claims description 44
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 39
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 39
- 229910052753 mercury Inorganic materials 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 35
- 238000005259 measurement Methods 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 238000004438 BET method Methods 0.000 claims description 34
- 238000002459 porosimetry Methods 0.000 claims description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 28
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 28
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 27
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 26
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 25
- 239000007787 solid Substances 0.000 claims description 25
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 24
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000010459 dolomite Substances 0.000 claims description 20
- 229910000514 dolomite Inorganic materials 0.000 claims description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- 238000000227 grinding Methods 0.000 claims description 19
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 18
- 239000011975 tartaric acid Substances 0.000 claims description 18
- 235000002906 tartaric acid Nutrition 0.000 claims description 18
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 17
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 15
- 235000011054 acetic acid Nutrition 0.000 claims description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 14
- 239000001530 fumaric acid Substances 0.000 claims description 13
- 235000011087 fumaric acid Nutrition 0.000 claims description 13
- 235000012245 magnesium oxide Nutrition 0.000 claims description 13
- 239000000395 magnesium oxide Substances 0.000 claims description 13
- 239000011976 maleic acid Substances 0.000 claims description 13
- 235000006408 oxalic acid Nutrition 0.000 claims description 13
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 12
- 239000001361 adipic acid Substances 0.000 claims description 12
- 235000011037 adipic acid Nutrition 0.000 claims description 12
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 12
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000019260 propionic acid Nutrition 0.000 claims description 12
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 11
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 150000001735 carboxylic acids Chemical class 0.000 claims description 9
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 8
- 239000000347 magnesium hydroxide Substances 0.000 claims description 8
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 8
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- 241000907663 Siproeta stelenes Species 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052984 zinc sulfide Inorganic materials 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 5
- 229960001126 alginic acid Drugs 0.000 claims description 5
- 150000004781 alginic acids Chemical class 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 5
- 239000008109 sodium starch glycolate Substances 0.000 claims description 5
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 229940032147 starch Drugs 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920002148 Gellan gum Polymers 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920001800 Shellac Polymers 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 229920013820 alkyl cellulose Chemical class 0.000 claims description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 235000010492 gellan gum Nutrition 0.000 claims description 4
- 239000000216 gellan gum Substances 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 229920013821 hydroxy alkyl cellulose Chemical class 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 4
- 239000004208 shellac Substances 0.000 claims description 4
- 229940113147 shellac Drugs 0.000 claims description 4
- 235000013874 shellac Nutrition 0.000 claims description 4
- 229940071117 starch glycolate Drugs 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- HHSPVTKDOHQBKF-UHFFFAOYSA-J calcium;magnesium;dicarbonate Chemical compound [Mg+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HHSPVTKDOHQBKF-UHFFFAOYSA-J 0.000 claims description 3
- 241000206672 Gelidium Species 0.000 claims 1
- 229960001708 magnesium carbonate Drugs 0.000 description 120
- 239000002002 slurry Substances 0.000 description 64
- 239000000047 product Substances 0.000 description 47
- 239000002243 precursor Substances 0.000 description 45
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 37
- 239000000843 powder Substances 0.000 description 33
- 239000013543 active substance Substances 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 32
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 27
- 239000004480 active ingredient Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 21
- 238000001035 drying Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 229910052783 alkali metal Inorganic materials 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 12
- 235000010216 calcium carbonate Nutrition 0.000 description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 description 11
- 229960003563 calcium carbonate Drugs 0.000 description 11
- 229940083542 sodium Drugs 0.000 description 11
- 235000015424 sodium Nutrition 0.000 description 11
- 239000003434 antitussive agent Substances 0.000 description 10
- 229940124584 antitussives Drugs 0.000 description 10
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 10
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 10
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 10
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 10
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 10
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 9
- 229960003088 loratadine Drugs 0.000 description 9
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 9
- 229960004127 naloxone Drugs 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000003172 expectorant agent Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 229960001680 ibuprofen Drugs 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 7
- 229960002965 pravastatin Drugs 0.000 description 7
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 101100190324 Pyrenochaetopsis sp phm2 gene Proteins 0.000 description 6
- 101100190325 Pyrenochaetopsis sp phm3 gene Proteins 0.000 description 6
- 101100190326 Pyrenochaetopsis sp phm4 gene Proteins 0.000 description 6
- 101100210186 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VTC1 gene Proteins 0.000 description 6
- 101100210189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VTC3 gene Proteins 0.000 description 6
- 101100210192 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VTC4 gene Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229940069428 antacid Drugs 0.000 description 6
- 239000003159 antacid agent Substances 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 6
- 229960001076 chlorpromazine Drugs 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229960002390 flurbiprofen Drugs 0.000 description 6
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 6
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 6
- 238000003801 milling Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229960003908 pseudoephedrine Drugs 0.000 description 6
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 5
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 5
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 5
- 239000004952 Polyamide Substances 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 229940125715 antihistaminic agent Drugs 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- 229960005274 benzocaine Drugs 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229960001803 cetirizine Drugs 0.000 description 5
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 5
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
- 229960001985 dextromethorphan Drugs 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000010685 fatty oil Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 229940068517 fruit extracts Drugs 0.000 description 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 229960004125 ketoconazole Drugs 0.000 description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 5
- 229960000991 ketoprofen Drugs 0.000 description 5
- 229960001571 loperamide Drugs 0.000 description 5
- 150000002681 magnesium compounds Chemical class 0.000 description 5
- 229960000869 magnesium oxide Drugs 0.000 description 5
- 229960001474 meclozine Drugs 0.000 description 5
- 229920002647 polyamide Polymers 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003784 tall oil Substances 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 4
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 4
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000005770 Eugenol Substances 0.000 description 4
- 244000194101 Ginkgo biloba Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 4
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 4
- 101150046866 PHM6 gene Proteins 0.000 description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 4
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 230000001773 anti-convulsant effect Effects 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 229960005370 atorvastatin Drugs 0.000 description 4
- 230000002902 bimodal effect Effects 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 239000003093 cationic surfactant Substances 0.000 description 4
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 4
- 229960001884 chlorhexidine diacetate Drugs 0.000 description 4
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 4
- 229960004170 clozapine Drugs 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 229960004126 codeine Drugs 0.000 description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000014134 echinacea Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229960002217 eugenol Drugs 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 229960004884 fluconazole Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012676 herbal extract Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004898 kneading Methods 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 229930007744 linalool Natural products 0.000 description 4
- 229960001929 meloxicam Drugs 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 229960002509 miconazole Drugs 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 229960002895 phenylbutazone Drugs 0.000 description 4
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 229960003310 sildenafil Drugs 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 235000011083 sodium citrates Nutrition 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 3
- OIGWAXDAPKFNCQ-UHFFFAOYSA-N 4-isopropylbenzyl alcohol Chemical compound CC(C)C1=CC=C(CO)C=C1 OIGWAXDAPKFNCQ-UHFFFAOYSA-N 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 101100190323 Caenorhabditis elegans phm-2 gene Proteins 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 244000133098 Echinacea angustifolia Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 239000005792 Geraniol Substances 0.000 description 3
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 101100078144 Mus musculus Msrb1 gene Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 3
- 101150118331 PHM7 gene Proteins 0.000 description 3
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101100190322 Pyrenochaetopsis sp phm1 gene Proteins 0.000 description 3
- 101100190327 Pyrenochaetopsis sp phm5 gene Proteins 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 101100353054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PPN1 gene Proteins 0.000 description 3
- 101100210188 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) VTC2 gene Proteins 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000000924 antiasthmatic agent Substances 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000003793 antidiarrheal agent Substances 0.000 description 3
- 229940125714 antidiarrheal agent Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003200 antithyroid agent Substances 0.000 description 3
- 229940043671 antithyroid preparations Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 229960001736 buprenorphine Drugs 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 3
- 229960001552 chlorprothixene Drugs 0.000 description 3
- 229960001380 cimetidine Drugs 0.000 description 3
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 3
- 229940117916 cinnamic aldehyde Drugs 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 238000005056 compaction Methods 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 229960001583 diphenhydramine citrate Drugs 0.000 description 3
- 229960001859 domiphen bromide Drugs 0.000 description 3
- 229960001971 ebastine Drugs 0.000 description 3
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 3
- 229940066493 expectorants Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 3
- 229960001596 famotidine Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229960003592 fexofenadine Drugs 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229940091249 fluoride supplement Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 229940113087 geraniol Drugs 0.000 description 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 3
- 229960001410 hydromorphone Drugs 0.000 description 3
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960004130 itraconazole Drugs 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 3
- 235000012680 lutein Nutrition 0.000 description 3
- 239000001656 lutein Substances 0.000 description 3
- 229960005375 lutein Drugs 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- BHQQXAOBIZQEGI-UHFFFAOYSA-N methyl 2-chlorobutanoate Chemical compound CCC(Cl)C(=O)OC BHQQXAOBIZQEGI-UHFFFAOYSA-N 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 239000008185 minitablet Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 229940066491 mucolytics Drugs 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 3
- 229960004872 nizatidine Drugs 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 229960002085 oxycodone Drugs 0.000 description 3
- 229960000762 perphenazine Drugs 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960003910 promethazine Drugs 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960001312 tiaprofenic acid Drugs 0.000 description 3
- BJIOGJUNALELMI-ONEGZZNKSA-N trans-isoeugenol Chemical compound COC1=CC(\C=C\C)=CC=C1O BJIOGJUNALELMI-ONEGZZNKSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229960002381 vardenafil Drugs 0.000 description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 3
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DMXUBGVVJLVCPB-UHFFFAOYSA-N (2,4,6-trimethylcyclohex-3-en-1-yl)methanol Chemical compound CC1CC(C)=CC(C)C1CO DMXUBGVVJLVCPB-UHFFFAOYSA-N 0.000 description 2
- DGEPZINOUXMMAS-UHFFFAOYSA-N (2,4-dimethylcyclohexyl)methanol Chemical compound CC1CCC(CO)C(C)C1 DGEPZINOUXMMAS-UHFFFAOYSA-N 0.000 description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
- KHWTYGFHPHRQMP-UHFFFAOYSA-N (4-propan-2-ylcyclohexyl)methanol Chemical compound CC(C)C1CCC(CO)CC1 KHWTYGFHPHRQMP-UHFFFAOYSA-N 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 2
- RXBQNMWIQKOSCS-UHFFFAOYSA-N (7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methanol Chemical compound C1C2C(C)(C)C1CC=C2CO RXBQNMWIQKOSCS-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZCHHRLHTBGRGOT-SNAWJCMRSA-N (E)-hex-2-en-1-ol Chemical compound CCC\C=C\CO ZCHHRLHTBGRGOT-SNAWJCMRSA-N 0.000 description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 2
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 2
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- CLFDIFDNDWRHJF-UHFFFAOYSA-N 2-(4-methylphenyl)-1-propanol Chemical compound OCC(C)C1=CC=C(C)C=C1 CLFDIFDNDWRHJF-UHFFFAOYSA-N 0.000 description 2
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 2
- WKHTUDYDJUHYMK-UHFFFAOYSA-N 2-cyclododecylpropan-1-ol Chemical compound OCC(C)C1CCCCCCCCCCC1 WKHTUDYDJUHYMK-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229930008411 3,7-dimethylocta-2,6-dien-1-ol Natural products 0.000 description 2
- GYSCXPVAKHVAAY-UHFFFAOYSA-N 3-Nonanol Chemical compound CCCCCCC(O)CC GYSCXPVAKHVAAY-UHFFFAOYSA-N 0.000 description 2
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 2
- IWTBVKIGCDZRPL-UHFFFAOYSA-N 3-methylpentanol Chemical compound CCC(C)CCO IWTBVKIGCDZRPL-UHFFFAOYSA-N 0.000 description 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 2
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 2
- CHWNEIVBYREQRF-UHFFFAOYSA-N 4-Ethyl-2-methoxyphenol Chemical compound CCC1=CC=C(O)C(OC)=C1 CHWNEIVBYREQRF-UHFFFAOYSA-N 0.000 description 2
- FWMPKHMKIJDEMJ-UHFFFAOYSA-N 4-allyl-2,6-dimethoxyphenol Chemical compound COC1=CC(CC=C)=CC(OC)=C1O FWMPKHMKIJDEMJ-UHFFFAOYSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 235000003880 Calendula Nutrition 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000735432 Hydrastis canadensis Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 2
- KEVYVLWNCKMXJX-ZCNNSNEGSA-N Isophytol Natural products CC(C)CCC[C@H](C)CCC[C@@H](C)CCC[C@@](C)(O)C=C KEVYVLWNCKMXJX-ZCNNSNEGSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- UUQHKWMIDYRWHH-UHFFFAOYSA-N Methyl beta-orcinolcarboxylate Chemical compound COC(=O)C1=C(C)C=C(O)C(C)=C1O UUQHKWMIDYRWHH-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- 235000000556 Paullinia cupana Nutrition 0.000 description 2
- 240000003444 Paullinia cupana Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 240000005546 Piper methysticum Species 0.000 description 2
- 235000016787 Piper methysticum Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 240000006661 Serenoa repens Species 0.000 description 2
- 235000005318 Serenoa repens Nutrition 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 2
- 229950010221 alexidine Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 2
- 150000004996 alkyl benzenes Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 229960004663 alminoprofen Drugs 0.000 description 2
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 2
- 229960002133 almotriptan Drugs 0.000 description 2
- UNMLVGNWZDHBRA-UFAVQCRNSA-N alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)CO3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O UNMLVGNWZDHBRA-UFAVQCRNSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003257 anti-anginal effect Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960005430 benoxaprofen Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960005400 bisoprolol fumarate Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 2
- 229960000725 brompheniramine Drugs 0.000 description 2
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 2
- 229960003108 brompheniramine maleate Drugs 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 229960001058 bupropion Drugs 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 2
- 229960003184 carprofen Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960004830 cetylpyridinium Drugs 0.000 description 2
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 235000000484 citronellol Nutrition 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000007336 cyanidin Nutrition 0.000 description 2
- 229960003564 cyclizine Drugs 0.000 description 2
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 229960001378 dequalinium chloride Drugs 0.000 description 2
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229960001271 desloratadine Drugs 0.000 description 2
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 229960004993 dimenhydrinate Drugs 0.000 description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- 229960005008 doxylamine succinate Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960002472 eletriptan Drugs 0.000 description 2
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- OMSUIQOIVADKIM-UHFFFAOYSA-N ethyl 3-hydroxybutyrate Chemical compound CCOC(=O)CC(C)O OMSUIQOIVADKIM-UHFFFAOYSA-N 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 229960004945 etoricoxib Drugs 0.000 description 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N exo-carveol Natural products CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 229960001395 fenbufen Drugs 0.000 description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000004083 gastrointestinal agent Substances 0.000 description 2
- 229940125695 gastrointestinal agent Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 235000005679 goldenseal Nutrition 0.000 description 2
- 229940107702 grapefruit seed extract Drugs 0.000 description 2
- 239000003630 growth substance Substances 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FXHGMKSSBGDXIY-UHFFFAOYSA-N heptanal Chemical compound CCCCCCC=O FXHGMKSSBGDXIY-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000544 hyperemic effect Effects 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 229960004187 indoprofen Drugs 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 229960001508 levocetirizine Drugs 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- UODXCYZDMHPIJE-UHFFFAOYSA-N menthanol Chemical compound CC1CCC(C(C)(C)O)CC1 UODXCYZDMHPIJE-UHFFFAOYSA-N 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 201000003152 motion sickness Diseases 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 229960005254 naratriptan Drugs 0.000 description 2
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960005118 oxymorphone Drugs 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- 229960004662 parecoxib Drugs 0.000 description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
- RUMOYJJNUMEFDD-UHFFFAOYSA-N perillyl aldehyde Chemical compound CC(=C)C1CCC(C=O)=CC1 RUMOYJJNUMEFDD-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960000851 pirprofen Drugs 0.000 description 2
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229960003101 pranoprofen Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 2
- 229960002244 promethazine hydrochloride Drugs 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229940018203 pyrilamine maleate Drugs 0.000 description 2
- 229960004157 rabeprazole Drugs 0.000 description 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229960000425 rizatriptan Drugs 0.000 description 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 229960003320 roxatidine Drugs 0.000 description 2
- 229960003287 roxatidine acetate Drugs 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 239000010018 saw palmetto extract Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229940107518 slippery elm bark Drugs 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
- 229960004291 sucralfate Drugs 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 229960004492 suprofen Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
- 229960002905 tolfenamic acid Drugs 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- BJIOGJUNALELMI-UHFFFAOYSA-N trans-isoeugenol Natural products COC1=CC(C=CC)=CC=C1O BJIOGJUNALELMI-UHFFFAOYSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- UKRXSDKQJLHHDN-UHFFFAOYSA-N undec-3-en-1-ol Chemical compound CCCCCCCC=CCCO UKRXSDKQJLHHDN-UHFFFAOYSA-N 0.000 description 2
- KMPQYAYAQWNLME-UHFFFAOYSA-N undecanal Chemical compound CCCCCCCCCCC=O KMPQYAYAQWNLME-UHFFFAOYSA-N 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229960002149 valganciclovir Drugs 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 238000001238 wet grinding Methods 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- JGQFVRIQXUFPAH-UHFFFAOYSA-N α-citronellol Chemical compound OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 description 1
- XGRCZWYTJSFHET-UHFFFAOYSA-N (2,4-dimethylcyclohex-3-en-1-yl)methanol Chemical compound CC1C=C(C)CCC1CO XGRCZWYTJSFHET-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000001414 (2E)-2-(phenylmethylidene)octanal Substances 0.000 description 1
- 239000001418 (2E)-2-benzylideneheptan-1-ol Substances 0.000 description 1
- AMXYRHBJZOVHOL-UHFFFAOYSA-N (2E,6E)-2,6-Nonadien-1-ol Natural products CCC=CCCC=CCO AMXYRHBJZOVHOL-UHFFFAOYSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001520 (2E,6Z)-nona-2,6-dien-1-ol Substances 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AMXYRHBJZOVHOL-DYWGDJMRSA-N (2e,6e)-nona-2,6-dien-1-ol Chemical compound CC\C=C\CC\C=C\CO AMXYRHBJZOVHOL-DYWGDJMRSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- BOGURUDKGWMRHN-CDJQDVQCSA-N (3e,5e)-2,6-dimethylocta-3,5-dien-2-ol Chemical compound CC\C(C)=C\C=C\C(C)(C)O BOGURUDKGWMRHN-CDJQDVQCSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- VZWLLIHMPDESOD-UHFFFAOYSA-N (4,6-dimethylcyclohex-3-en-1-yl)methanol Chemical compound CC1CC(C)=CCC1CO VZWLLIHMPDESOD-UHFFFAOYSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 1
- 239000001496 (E)-2-methyl-3-phenylprop-2-enal Substances 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-DAXSKMNVSA-N (Z)-3-phenyl-2-propenal Chemical compound O=C\C=C/C1=CC=CC=C1 KJPRLNWUNMBNBZ-DAXSKMNVSA-N 0.000 description 1
- XJHRZBIBSSVCEL-ARJAWSKDSA-N (Z)-non-6-en-1-ol Chemical compound CC\C=C/CCCCCO XJHRZBIBSSVCEL-ARJAWSKDSA-N 0.000 description 1
- 239000001586 (Z)-pent-2-en-1-ol Substances 0.000 description 1
- LLNAMUJRIZIXHF-VQHVLOKHSA-N (e)-2-methyl-3-phenylprop-2-en-1-ol Chemical compound OCC(/C)=C/C1=CC=CC=C1 LLNAMUJRIZIXHF-VQHVLOKHSA-N 0.000 description 1
- VLUMOWNVWOXZAU-VQHVLOKHSA-N (e)-2-methyl-3-phenylprop-2-enal Chemical compound O=CC(/C)=C/C1=CC=CC=C1 VLUMOWNVWOXZAU-VQHVLOKHSA-N 0.000 description 1
- SZPKMIRLEAFMBV-ZZXKWVIFSA-N (e)-3-methylpent-3-en-1-ol Chemical compound C\C=C(/C)CCO SZPKMIRLEAFMBV-ZZXKWVIFSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- HPSZLHZEQBRQIA-CMDGGOBGSA-N (e)-dodec-4-en-1-ol Chemical compound CCCCCCC\C=C\CCCO HPSZLHZEQBRQIA-CMDGGOBGSA-N 0.000 description 1
- KANHUDSFOMPVGY-AATRIKPKSA-N (e)-non-4-en-1-ol Chemical compound CCCC\C=C\CCCO KANHUDSFOMPVGY-AATRIKPKSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 1
- UPMAOXLCTXPPAG-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol Chemical compound C1CCCC2CC(O)CCC21 UPMAOXLCTXPPAG-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ODZDJYUDIATMEL-UHFFFAOYSA-N 1,2-dimethyl-3-prop-1-en-2-ylcyclopent-2-en-1-ol Chemical compound CC(=C)C1=C(C)C(C)(O)CC1 ODZDJYUDIATMEL-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- NEHPIUGJDUWSRR-UHFFFAOYSA-N 1-(4-propan-2-ylcyclohexyl)ethanol Chemical compound CC(C)C1CCC(C(C)O)CC1 NEHPIUGJDUWSRR-UHFFFAOYSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-UHFFFAOYSA-N 1-phenylethanol Chemical compound CC(O)C1=CC=CC=C1 WAPNOHKVXSQRPX-UHFFFAOYSA-N 0.000 description 1
- OLUJUQKZMDLFII-UHFFFAOYSA-N 1-phenyloct-1-en-3-ol Chemical compound CCCCCC(O)C=CC1=CC=CC=C1 OLUJUQKZMDLFII-UHFFFAOYSA-N 0.000 description 1
- GIEMHYCMBGELGY-UHFFFAOYSA-N 10-undecen-1-ol Chemical compound OCCCCCCCCCC=C GIEMHYCMBGELGY-UHFFFAOYSA-N 0.000 description 1
- YQQSRZSUGBETRS-UHFFFAOYSA-N 1h-pyridazine-6-thione Chemical compound SC1=CC=CN=N1 YQQSRZSUGBETRS-UHFFFAOYSA-N 0.000 description 1
- IRPGOXJVTQTAAN-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanal Chemical compound FC(F)(F)C(F)(F)C=O IRPGOXJVTQTAAN-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- YBRHBMHQQIEOOL-UHFFFAOYSA-N 2,4-dimethylhepta-2,6-dien-1-ol Chemical compound C=CCC(C)C=C(C)CO YBRHBMHQQIEOOL-UHFFFAOYSA-N 0.000 description 1
- XSNQECSCDATQEL-SECBINFHSA-N 2,6-dimethyl-7-octen-2-ol Chemical compound C=C[C@@H](C)CCCC(C)(C)O XSNQECSCDATQEL-SECBINFHSA-N 0.000 description 1
- WRFXXJKURVTLSY-UHFFFAOYSA-N 2,6-dimethyloctan-2-ol Chemical compound CCC(C)CCCC(C)(C)O WRFXXJKURVTLSY-UHFFFAOYSA-N 0.000 description 1
- MSDBCXHVDKLCCF-UHFFFAOYSA-N 2,6-dimethyloctan-3-ol Chemical compound CCC(C)CCC(O)C(C)C MSDBCXHVDKLCCF-UHFFFAOYSA-N 0.000 description 1
- RUGISKODRCWQNE-UHFFFAOYSA-N 2-(2-methylphenyl)ethanol Chemical compound CC1=CC=CC=C1CCO RUGISKODRCWQNE-UHFFFAOYSA-N 0.000 description 1
- KWHVBVJDKLSOTB-UHFFFAOYSA-N 2-(3-methylphenyl)ethanol Chemical compound CC1=CC=CC(CCO)=C1 KWHVBVJDKLSOTB-UHFFFAOYSA-N 0.000 description 1
- FFWXHQFJNOGDJE-UHFFFAOYSA-N 2-(4-methylphenoxy)ethanol Chemical compound CC1=CC=C(OCCO)C=C1 FFWXHQFJNOGDJE-UHFFFAOYSA-N 0.000 description 1
- DAVFJRVIVZOKKS-UHFFFAOYSA-N 2-(4-methylphenyl)ethanol Chemical compound CC1=CC=C(CCO)C=C1 DAVFJRVIVZOKKS-UHFFFAOYSA-N 0.000 description 1
- ROKSAUSPJGWCSM-UHFFFAOYSA-N 2-(7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)ethanol Chemical compound C1C2C(C)(C)C1CC=C2CCO ROKSAUSPJGWCSM-UHFFFAOYSA-N 0.000 description 1
- BANIDACEBXZGNK-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-phenylcyclopentane-1-carboxylate;ethane-1,2-disulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O.C=1C=CC=CC=1C1(C(=O)OCCN(CC)CC)CCCC1.C=1C=CC=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 BANIDACEBXZGNK-UHFFFAOYSA-N 0.000 description 1
- LIPHCKNQPJXUQF-SDNWHVSQSA-N 2-Benzylidene-1-heptanol Chemical compound CCCCC\C(CO)=C/C1=CC=CC=C1 LIPHCKNQPJXUQF-SDNWHVSQSA-N 0.000 description 1
- RADIRXJQODWKGQ-HWKANZROSA-N 2-Ethoxy-5-(1-propenyl)phenol Chemical compound CCOC1=CC=C(\C=C\C)C=C1O RADIRXJQODWKGQ-HWKANZROSA-N 0.000 description 1
- RNDNSYIPLPAXAZ-UHFFFAOYSA-N 2-Phenyl-1-propanol Chemical compound OCC(C)C1=CC=CC=C1 RNDNSYIPLPAXAZ-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- WGDADRBTCPGSDG-UHFFFAOYSA-N 2-[[4,5-bis(4-chlorophenyl)-1,3-oxazol-2-yl]sulfanyl]propanoic acid Chemical compound O1C(SC(C)C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(Cl)C=C1 WGDADRBTCPGSDG-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QJQZRLXDLORINA-UHFFFAOYSA-N 2-cyclohexylethanol Chemical compound OCCC1CCCCC1 QJQZRLXDLORINA-UHFFFAOYSA-N 0.000 description 1
- IRIVQXLOJHCXIE-UHFFFAOYSA-N 2-cyclohexylpropan-1-ol Chemical compound OCC(C)C1CCCCC1 IRIVQXLOJHCXIE-UHFFFAOYSA-N 0.000 description 1
- GQENNFHUCSKOPN-UHFFFAOYSA-N 2-ethoxy-4-hydroxybenzaldehyde Chemical compound CCOC1=CC(O)=CC=C1C=O GQENNFHUCSKOPN-UHFFFAOYSA-N 0.000 description 1
- ZWQBCCVEOIYNDL-UHFFFAOYSA-N 2-ethoxy-4-methylphenol Chemical compound CCOC1=CC(C)=CC=C1O ZWQBCCVEOIYNDL-UHFFFAOYSA-N 0.000 description 1
- CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 1
- LLNAMUJRIZIXHF-UHFFFAOYSA-N 2-methyl-3-phenylprop-2-en-1-ol Chemical compound OCC(C)=CC1=CC=CC=C1 LLNAMUJRIZIXHF-UHFFFAOYSA-N 0.000 description 1
- LTZKHYYXQWNXPU-UHFFFAOYSA-N 2-methyl-3-phenylpropan-1-ol Chemical compound OCC(C)CC1=CC=CC=C1 LTZKHYYXQWNXPU-UHFFFAOYSA-N 0.000 description 1
- SXGYZCMGVZKIPJ-UHFFFAOYSA-N 2-methyl-4-phenylpentan-1-ol Chemical compound OCC(C)CC(C)C1=CC=CC=C1 SXGYZCMGVZKIPJ-UHFFFAOYSA-N 0.000 description 1
- DRTBYQJIHFSKDT-UHFFFAOYSA-N 2-methyl-5-phenylpentan-1-ol Chemical compound OCC(C)CCCC1=CC=CC=C1 DRTBYQJIHFSKDT-UHFFFAOYSA-N 0.000 description 1
- MNXNDLQGVDOJQY-UHFFFAOYSA-N 2-methylnonanal Chemical compound CCCCCCCC(C)C=O MNXNDLQGVDOJQY-UHFFFAOYSA-N 0.000 description 1
- KBCNUEXDHWDIFX-UHFFFAOYSA-N 2-methyloctan-2-ol Chemical compound CCCCCCC(C)(C)O KBCNUEXDHWDIFX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- IKEHOXWJQXIQAG-UHFFFAOYSA-N 2-tert-butyl-4-methylphenol Chemical compound CC1=CC=C(O)C(C(C)(C)C)=C1 IKEHOXWJQXIQAG-UHFFFAOYSA-N 0.000 description 1
- BRRVXFOKWJKTGG-UHFFFAOYSA-N 3,3,5-trimethylcyclohexanol Chemical compound CC1CC(O)CC(C)(C)C1 BRRVXFOKWJKTGG-UHFFFAOYSA-N 0.000 description 1
- NPHCXUPGMINOPP-UHFFFAOYSA-N 3,6-dimethyloctan-3-ol Chemical compound CCC(C)CCC(C)(O)CC NPHCXUPGMINOPP-UHFFFAOYSA-N 0.000 description 1
- KEVYVLWNCKMXJX-UHFFFAOYSA-N 3,7,11,15-tetramethylhexadec-1-en-3-ol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C=C KEVYVLWNCKMXJX-UHFFFAOYSA-N 0.000 description 1
- DLHQZZUEERVIGQ-UHFFFAOYSA-N 3,7-dimethyl-3-octanol Chemical compound CCC(C)(O)CCCC(C)C DLHQZZUEERVIGQ-UHFFFAOYSA-N 0.000 description 1
- PRNCMAKCNVRZFX-UHFFFAOYSA-N 3,7-dimethyloctan-1-ol Chemical compound CC(C)CCCC(C)CCO PRNCMAKCNVRZFX-UHFFFAOYSA-N 0.000 description 1
- JOUWVJULHKPDHV-UHFFFAOYSA-N 3,7-dimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.CN1C(=O)NC(=O)C2=C1N=CN2C JOUWVJULHKPDHV-UHFFFAOYSA-N 0.000 description 1
- NOXNCSQBTYNMHD-UHFFFAOYSA-N 3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine;hydron;chloride Chemical compound Cl.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 NOXNCSQBTYNMHD-UHFFFAOYSA-N 0.000 description 1
- BWVZAZPLUTUBKD-UHFFFAOYSA-N 3-(5,6,6-Trimethylbicyclo[2.2.1]hept-1-yl)cyclohexanol Chemical compound CC1(C)C(C)C2CC1CC2C1CCCC(O)C1 BWVZAZPLUTUBKD-UHFFFAOYSA-N 0.000 description 1
- NSPPRYXGGYQMPY-UHFFFAOYSA-N 3-Methylbuten-2-ol-1 Natural products CC(C)C(O)=C NSPPRYXGGYQMPY-UHFFFAOYSA-N 0.000 description 1
- GTNCESCYZPMXCJ-UHFFFAOYSA-N 3-Phenylpropyl propanoate Chemical compound CCC(=O)OCCCC1=CC=CC=C1 GTNCESCYZPMXCJ-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- JEWXYDDSLPIBBO-UHFFFAOYSA-N 3-methyl-3-octanol Chemical compound CCCCCC(C)(O)CC JEWXYDDSLPIBBO-UHFFFAOYSA-N 0.000 description 1
- OXYRENDGHPGWKV-UHFFFAOYSA-N 3-methyl-5-phenylpentan-1-ol Chemical compound OCCC(C)CCC1=CC=CC=C1 OXYRENDGHPGWKV-UHFFFAOYSA-N 0.000 description 1
- DRKRLMZMGTWUSQ-UHFFFAOYSA-N 3-methyloct-1-en-3-ol Chemical compound CCCCCC(C)(O)C=C DRKRLMZMGTWUSQ-UHFFFAOYSA-N 0.000 description 1
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 1
- SVYBEBLNQGDRHF-UHFFFAOYSA-N 4-amino-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound S1C(CC)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 SVYBEBLNQGDRHF-UHFFFAOYSA-N 0.000 description 1
- YXVSKJDFNJFXAJ-UHFFFAOYSA-N 4-cyclohexyl-2-methylbutan-2-ol Chemical compound CC(C)(O)CCC1=CC=CC=C1 YXVSKJDFNJFXAJ-UHFFFAOYSA-N 0.000 description 1
- QKJHNPXSYSFZMJ-UHFFFAOYSA-N 4-ethenyl-2-methylphenol Chemical compound CC1=CC(C=C)=CC=C1O QKJHNPXSYSFZMJ-UHFFFAOYSA-N 0.000 description 1
- BLLRZXYXUWMGHJ-UHFFFAOYSA-N 4-ethenyl-4,7-dimethyloct-6-en-3-ol Chemical compound CCC(O)C(C)(C=C)CC=C(C)C BLLRZXYXUWMGHJ-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 229940094970 4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol Drugs 0.000 description 1
- IUADYGVMSDKSMB-UHFFFAOYSA-N 4-methyl-1-phenylpentan-2-ol Chemical compound CC(C)CC(O)CC1=CC=CC=C1 IUADYGVMSDKSMB-UHFFFAOYSA-N 0.000 description 1
- BCDGREOJJCLPJD-UHFFFAOYSA-N 4-methyl-2-prop-1-en-2-ylhex-4-en-1-ol Chemical compound CC=C(C)CC(CO)C(C)=C BCDGREOJJCLPJD-UHFFFAOYSA-N 0.000 description 1
- KMTDMTZBNYGUNX-UHFFFAOYSA-N 4-methylbenzyl alcohol Chemical compound CC1=CC=C(CO)C=C1 KMTDMTZBNYGUNX-UHFFFAOYSA-N 0.000 description 1
- ZIJWGEHOVHJHKB-UHFFFAOYSA-N 4-phenylbut-3-en-2-ol Chemical compound CC(O)C=CC1=CC=CC=C1 ZIJWGEHOVHJHKB-UHFFFAOYSA-N 0.000 description 1
- QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 description 1
- VUGJPGPMYGKRPW-UHFFFAOYSA-N 5-methyl-2-propan-2-ylhex-2-en-1-ol Chemical compound CC(C)CC=C(CO)C(C)C VUGJPGPMYGKRPW-UHFFFAOYSA-N 0.000 description 1
- NXQJDVBMMRCKQG-UHFFFAOYSA-N 5-phenylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1C1=CC=CC=C1 NXQJDVBMMRCKQG-UHFFFAOYSA-N 0.000 description 1
- RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- QZZFUPSRNBMJPU-UHFFFAOYSA-N 6-methyltridec-5-en-2-ol Chemical compound CCCCCCCC(C)=CCCC(C)O QZZFUPSRNBMJPU-UHFFFAOYSA-N 0.000 description 1
- AZUVBPVDRHGGEP-UHFFFAOYSA-N 6a,9a-dimethyl-4,5,7,8,9,9a-hexahydro-6aH-dipyrrolo(2,3-b;3',2',1'-hi)indole Natural products CC(=C)C1CCC(C)=CCCC(C)=CCCC(C)=CC1O AZUVBPVDRHGGEP-UHFFFAOYSA-N 0.000 description 1
- ZJVRYPHKSDHLTC-UHFFFAOYSA-N 7-methoxy-3,7-dimethyloctan-2-ol Chemical compound COC(C)(C)CCCC(C)C(C)O ZJVRYPHKSDHLTC-UHFFFAOYSA-N 0.000 description 1
- QDTDKYHPHANITQ-UHFFFAOYSA-N 7-methyloctan-1-ol Chemical compound CC(C)CCCCCCO QDTDKYHPHANITQ-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminum fluoride Inorganic materials F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 description 1
- RANVDUNFZBMTBK-UHFFFAOYSA-N Amyl salicylate Chemical compound CCCCCOC(=O)C1=CC=CC=C1O RANVDUNFZBMTBK-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 244000284152 Carapichea ipecacuanha Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 244000119298 Emblica officinalis Species 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DUKPKQFHJQGTGU-UHFFFAOYSA-N Hexyl salicylic acid Chemical compound CCCCCCOC(=O)C1=CC=CC=C1O DUKPKQFHJQGTGU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 229940124836 Imigra Drugs 0.000 description 1
- 239000009471 Ipecac Substances 0.000 description 1
- PMGCQNGBLMMXEW-UHFFFAOYSA-N Isoamyl salicylate Chemical compound CC(C)CCOC(=O)C1=CC=CC=C1O PMGCQNGBLMMXEW-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- BRHDDEIRQPDPMG-UHFFFAOYSA-N Linalyl oxide Chemical compound CC(C)(O)C1CCC(C)(C=C)O1 BRHDDEIRQPDPMG-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
- 229910020091 MgCa Inorganic materials 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101100003996 Mus musculus Atrn gene Proteins 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- RXBQNMWIQKOSCS-RKDXNWHRSA-N Myrtenol Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2CO RXBQNMWIQKOSCS-RKDXNWHRSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- MCFAPRSDPYRJJP-UHFFFAOYSA-N N,N-diphenylaniline 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.c1ccc(cc1)N(c1ccccc1)c1ccccc1 MCFAPRSDPYRJJP-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 description 1
- 239000000866 Neuromuscular Agent Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- JIFPTBLGXRKRAO-UHFFFAOYSA-L O.[Al+3].S(=O)(=O)([O-])[O-].[Mg+2] Chemical compound O.[Al+3].S(=O)(=O)([O-])[O-].[Mg+2] JIFPTBLGXRKRAO-UHFFFAOYSA-L 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- YNMSDIQQNIRGDP-UHFFFAOYSA-N Phenethyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCCC1=CC=CC=C1 YNMSDIQQNIRGDP-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- BHUIUXNAPJIDOG-UHFFFAOYSA-N Piperonol Chemical compound OCC1=CC=C2OCOC2=C1 BHUIUXNAPJIDOG-UHFFFAOYSA-N 0.000 description 1
- 235000016551 Potentilla erecta Nutrition 0.000 description 1
- 240000000103 Potentilla erecta Species 0.000 description 1
- 239000005820 Prochloraz Substances 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 241000304405 Sedum burrito Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- XJHRZBIBSSVCEL-UHFFFAOYSA-N Z-Non-6-en-1-ol Natural products CCC=CCCCCCO XJHRZBIBSSVCEL-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000005870 Ziram Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- HMKKIXGYKWDQSV-KAMYIIQDSA-N alpha-Amylcinnamaldehyde Chemical compound CCCCC\C(C=O)=C\C1=CC=CC=C1 HMKKIXGYKWDQSV-KAMYIIQDSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940090971 alpha-amylcinnamyl alcohol Drugs 0.000 description 1
- 229940072717 alpha-hexylcinnamaldehyde Drugs 0.000 description 1
- GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical compound CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N alpha-methylbenzylalcohol Natural products CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 1
- GUUHFMWKWLOQMM-UHFFFAOYSA-N alpha-n-hexylcinnamic aldehyde Natural products CCCCCCC(C=O)=CC1=CC=CC=C1 GUUHFMWKWLOQMM-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- GSWGDDYIUCWADU-UHFFFAOYSA-N aluminum magnesium oxygen(2-) Chemical compound [O--].[Mg++].[Al+3] GSWGDDYIUCWADU-UHFFFAOYSA-N 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000000228 antimanic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229940029995 appetite stimulants Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 239000010516 ayurvedic herbal oil Substances 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- 229960002617 azatadine maleate Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 description 1
- 229960003789 benzonatate Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 229940104825 bismuth aluminate Drugs 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229940036348 bismuth carbonate Drugs 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008376 breath freshener Substances 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229910052599 brucite Inorganic materials 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 229940095626 calcium fluoride Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- GFIKIVSYJDVOOZ-UHFFFAOYSA-L calcium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [Ca+2].[O-]P([O-])(F)=O GFIKIVSYJDVOOZ-UHFFFAOYSA-L 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960001071 caramiphen edisylate Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940041750 cesamet Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-YKVZVUFRSA-N clemastine fumarate Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-YKVZVUFRSA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940068796 clozaril Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960001012 codeine hydrochloride Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 229940019836 cyclamen aldehyde Drugs 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- ACUZDYFTRHEKOS-UHFFFAOYSA-N decan-2-ol Chemical compound CCCCCCCCC(C)O ACUZDYFTRHEKOS-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- SAEOCANGOMBQSP-UHFFFAOYSA-N diazanium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [NH4+].[NH4+].[O-]P([O-])(F)=O SAEOCANGOMBQSP-UHFFFAOYSA-N 0.000 description 1
- GMZOPRQQINFLPQ-UHFFFAOYSA-H dibismuth;tricarbonate Chemical compound [Bi+3].[Bi+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GMZOPRQQINFLPQ-UHFFFAOYSA-H 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- FXNRKXSSLJKNGH-UHFFFAOYSA-L dipotassium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [K+].[K+].[O-]P([O-])(F)=O FXNRKXSSLJKNGH-UHFFFAOYSA-L 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- JLQAHGGMRAJUMJ-UHFFFAOYSA-N dodec-10-en-1-ol Chemical compound CC=CCCCCCCCCCO JLQAHGGMRAJUMJ-UHFFFAOYSA-N 0.000 description 1
- MLRYPOCSLBIUHY-UHFFFAOYSA-N dodec-2-en-1-ol Chemical compound CCCCCCCCCC=CCO MLRYPOCSLBIUHY-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- KNZADIMHVBBPOA-UHFFFAOYSA-N dyclonine hydrochloride Chemical compound [Cl-].C1=CC(OCCCC)=CC=C1C(=O)CC[NH+]1CCCCC1 KNZADIMHVBBPOA-UHFFFAOYSA-N 0.000 description 1
- 229960003462 dyclonine hydrochloride Drugs 0.000 description 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 1
- 229950002377 ebrotidine Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- DVIBDQWVFHDBOP-UHFFFAOYSA-N ethyl 3-hydroxy-3-phenylpropanoate Chemical compound CCOC(=O)CC(O)C1=CC=CC=C1 DVIBDQWVFHDBOP-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000002871 fertility agent Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- UFLHIIWVXFIJGU-UHFFFAOYSA-N hex-3-en-1-ol Natural products CCC=CCCO UFLHIIWVXFIJGU-UHFFFAOYSA-N 0.000 description 1
- PDSAKIXGSONUIX-UHFFFAOYSA-N hexaaluminum;dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3] PDSAKIXGSONUIX-UHFFFAOYSA-N 0.000 description 1
- UOVKYUCEFPSRIJ-UHFFFAOYSA-D hexamagnesium;tetracarbonate;dihydroxide;pentahydrate Chemical compound O.O.O.O.O.[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O UOVKYUCEFPSRIJ-UHFFFAOYSA-D 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- JEFJSEIUEJBMSR-UHFFFAOYSA-N hydron;n-phenylaniline;chloride Chemical compound Cl.C=1C=CC=CC=1NC1=CC=CC=C1 JEFJSEIUEJBMSR-UHFFFAOYSA-N 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940029408 ipecac Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QVDTXNVYSHVCGW-ONEGZZNKSA-N isopentenol Chemical compound CC(C)\C=C\O QVDTXNVYSHVCGW-ONEGZZNKSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 229940063718 lodine Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229960004018 magaldrate Drugs 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 description 1
- 235000011160 magnesium carbonates Nutrition 0.000 description 1
- 229940004916 magnesium glycinate Drugs 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 229930002897 methoprene Natural products 0.000 description 1
- 229950003442 methoprene Drugs 0.000 description 1
- 229960005192 methoxamine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003750 molluscacide Substances 0.000 description 1
- 230000002013 molluscicidal effect Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- DUNCVNHORHNONW-UHFFFAOYSA-N myrcenol Chemical compound CC(C)(O)CCCC(=C)C=C DUNCVNHORHNONW-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- BZZWJHLTQAJBKB-UHFFFAOYSA-N non-6-en-3-ol Chemical compound CCC=CCCC(O)CC BZZWJHLTQAJBKB-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 1
- AYQPVPFZWIQERS-UHFFFAOYSA-N oct-2-en-1-ol Chemical compound CCCCCC=CCO AYQPVPFZWIQERS-UHFFFAOYSA-N 0.000 description 1
- VVZFZHROKHLRJT-UHFFFAOYSA-N octadec-1-en-1-amine;hydrofluoride Chemical compound F.CCCCCCCCCCCCCCCCC=CN VVZFZHROKHLRJT-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940105606 oxycontin Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 description 1
- 229960001526 phenyltoloxamine Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229940106587 pine bark extract Drugs 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 229940081310 piperonal Drugs 0.000 description 1
- 229940124837 pisatidine Drugs 0.000 description 1
- 229960005455 polacrilin Drugs 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940063566 proventil Drugs 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- 229960004159 pseudoephedrine sulfate Drugs 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 1
- 238000009895 reductive bleaching Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000407 respiratory system agent Substances 0.000 description 1
- 229940125704 respiratory tract agent Drugs 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 description 1
- 229960005077 sodium picosulfate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 229960002573 sultiame Drugs 0.000 description 1
- 239000012756 surface treatment agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229940010017 tavist Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 239000002424 termiticide Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- RBNWAMSGVWEHFP-WAAGHKOSSA-N terpin Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(O)CC1 RBNWAMSGVWEHFP-WAAGHKOSSA-N 0.000 description 1
- 229950010257 terpin Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229950006150 tioxaprofen Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 239000008377 tooth whitener Substances 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylene diamine Substances C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- SISHRPQNHQRWQH-UHFFFAOYSA-N undec-5-en-1-ol Chemical compound CCCCCC=CCCCCO SISHRPQNHQRWQH-UHFFFAOYSA-N 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- ZFNVDHOSLNRHNN-UHFFFAOYSA-N xi-3-(4-Isopropylphenyl)-2-methylpropanal Chemical compound O=CC(C)CC1=CC=C(C(C)C)C=C1 ZFNVDHOSLNRHNN-UHFFFAOYSA-N 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- DUBNHZYBDBBJHD-UHFFFAOYSA-L ziram Chemical compound [Zn+2].CN(C)C([S-])=S.CN(C)C([S-])=S DUBNHZYBDBBJHD-UHFFFAOYSA-L 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09C—TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES ; PREPARATION OF CARBON BLACK ; PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS
- C09C1/00—Treatment of specific inorganic materials other than fibrous fillers; Preparation of carbon black
- C09C1/02—Compounds of alkaline earth metals or magnesium
- C09C1/028—Compounds containing only magnesium as metal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F5/00—Compounds of magnesium
- C01F5/24—Magnesium carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/30—Particle morphology extending in three dimensions
- C01P2004/32—Spheres
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/50—Agglomerated particles
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/51—Particles with a specific particle size distribution
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/10—Solid density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/12—Surface area
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/19—Oil-absorption capacity, e.g. DBP values
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/21—Attrition-index or crushing strength of granulates
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/22—Rheological behaviour as dispersion, e.g. viscosity, sedimentation stability
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Geology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于生产包含含镁离子材料的粒料的方法,包含该含镁离子材料的粒料以及该粒料在营养产品、农业产品、兽医产品、化妆产品中、优选在干化妆品和/或干皮肤护理组合物中、在家用产品、食物产品、包装产品、个人护理产品中、优选在口腔护理组合物中、在空气处理和水处理中、或者在药物产品中作为赋形剂的用途。
Description
技术领域
本发明涉及一种用于生产包含含镁离子材料的粒料(granules)的方法,包含该含镁离子材料的粒料以及该粒料在营养产品、农业产品、兽医产品、化妆产品中、优选在干化妆品和/或干皮肤护理组合物中、在家用产品、食物产品、包装产品、个人护理产品中、优选在口腔护理组合物中、在空气处理和水处理中、或者在药物产品中作为赋形剂的用途。
背景技术
在许多应用中,例如药物、营养品、农业、兽医、化妆品、家用、食品、包装、个人护理产品、在空气处理中和在水处理中,粒料具有相当的重要性,并且比粉末更为优选。因此,导致获得典型地具有0.2-4.0mm的尺寸的粒料(取决于其后续用途)的粉末团聚被广泛地用于改善粉末的物理性能如润湿性、流动性、堆密度和产品外观。
此外还进行造粒以例如防止粉末混合物的成分分离、防止起尘或改善流动性。
造粒(即其中使得初级粉末粒子粘附以形成更大的多粒子实体的过程)是通过在粒子之间产生结合(例如通过粘结剂)而将粒子聚集在一起的过程。
最重要的造粒类型之一是湿法造粒,其中通过将造粒液体添加到粉末床上(在叶轮的影响下)来形成粒料。在系统中产生的搅拌以及配制剂内组分的润湿一起导致初级粉末粒子的团聚以产生湿粒料。该造粒液体包含溶剂,该溶剂必须是挥发性的以便可通过干燥去除,并且是无毒的。混合到粉末中的水可在粉末粒子之间形成强至足以将它们锁定在一起的结合。然而,一旦水干燥,团聚体可能会散开。因此,水可能不足以强至形成和保持结合。在这种情况下,造粒液体包含粘结剂。
关于经表面反应碳酸镁,粒料也是通常已知的。例如,在EP3733785A1中提到从其中描述的方法获得的经表面反应碳酸镁可以是递送系统的一部分,该递送系统可以是自由流动的粉末、片剂、丸粒或粒料的形式。类似地,EP3517502 A1涉及一种用于释放家用护理配制剂中的一种或多种活性剂的递送系统,所述递送系统包含由碳酸镁组成的载体材料,该碳酸镁具有≥25m2/g的比表面积,使用氮气和BET法(根据ISO 9277:2010)测量,其中该递送系统可以是粉末、片剂、丸粒或粒料的形式。
然而,通过现有技术的方法(例如通过(湿法)造粒)获得的粒料具有多种缺点,例如较差的堆密度、流动性能和压实性以及低的机械稳定性。此外,湿法造粒需要使用不太有利的粘结剂。
因此,含镁离子材料可以使用各种方法进行造粒,但是,传统方法在没有粘结剂的情况下不能提供所需的结果,即高的堆密度、流动性能和压实性以及高机械稳定性。
发明内容
因此,本发明的一个目的在于提供一种用于生产包含含镁离子材料的粒料的方法,该粒料具有高的堆密度、流动性能和压实性以及高机械稳定性。本发明的另一个目的是在不使用粘结剂的情况下改善上述特性。
上述目的以及其他目的中的一个或多个由在此在独立权利要求中定义的主题来解决。本发明的有利实施方案在相应的从属权利要求中定义。
本发明因而涉及一种用于生产包含含镁离子材料的粒料的方法,该方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,以及
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料。
根据一种实施方案,步骤a)的含镁离子材料选自含氢氧化镁材料、含碳酸镁材料、含氧化镁材料及其混合物,优选地,步骤a)的含镁离子材料是含碳酸镁材料,选自白云石(CaMg(CO3)2)、无水碳酸镁或菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),纤菱镁矿(Mg2(CO3)(OH)2·3H2O),球碳镁石(Mg5(CO3)4(OH)2·5H2O),异水菱镁矿(Mg5(CO3)4(OH)2·5H2O),镁白孔雀石(Mg2(CO3)(OH)2·0.5H2O),水碳镁石(MgCO3·2H2O),多水菱镁矿(MgCO3·5H2O),白云质碳酸盐(dolocarbonate)和三水菱镁矿(MgCO3·3H2O),更优选地,步骤a)的含镁离子材料是水菱镁矿,例如天然或合成水菱镁矿。
根据另一种实施方案,步骤a)的含镁离子材料是经表面反应的含碳酸镁材料,其通过用一种或多种化合物处理含碳酸镁材料的表面而获得,所述化合物选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或者其相应的盐。
根据又另一种实施方案,步骤a)的含镁离子材料具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
根据一种实施方案,步骤a)的水性悬浮液具有基于该水性悬浮液的总重量计为1-40%重量、优选5-35%重量、最优选7-26%重量的固体含量。
根据另一种实施方案,在步骤b)之前和/或期间和/或之后添加至少一种崩解剂,优选地,该至少一种崩解剂选自交联羧甲基纤维素钠、改性纤维素胶、不溶性交联聚乙烯吡咯烷酮、淀粉、改性淀粉、淀粉羟乙酸盐如淀粉羟乙酸钠、微晶纤维素、预糊化淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、N-乙烯基-2-吡咯烷酮的均聚物、烷基纤维素酯、羟烷基纤维素酯、羧基烷基纤维素酯、藻酸、微晶纤维素及其多晶型、离子交换树脂、树胶、甲壳素、壳聚糖、粘土、结冷胶、交联泼拉克林(polacrillin)共聚物、琼脂、明胶、糊精、丙烯酸聚合物、羧甲基纤维素钠/钙、邻苯二甲酸羟丙基甲基纤维素、虫胶、泡腾混合物如碳酸氢盐组合一种或多种酸如柠檬酸或酒石酸、或其混合物。
根据再另一种实施方案,该至少一种崩解剂在步骤b)之前和/或期间和/或之后以0.1-10%重量、优选0.3-10%重量、更优选0.5-8%重量、最优选1-约5%重量的量添加,基于该含镁离子材料的总干重计。
根据一种实施方案,步骤b)中的均化进行一次或多次,优选1-5次,更优选1-3次。
根据另一种实施方案,步骤b)中的均化通过研磨进行。
根据又另一种实施方案,步骤b)中的均化在以下条件下进行:
a)50-900巴、优选100-750巴、最优选130-650巴的压力,和/或
b)5-95℃、优选10-80℃、最优选15-60℃的初始温度。
根据一种实施方案,步骤c)中的喷雾干燥在以下条件下进行:
a)0.1-300巴、优选1-100巴、更优选1至<50巴、最优选1-25巴的进料压力,和/或
b)120-950℃、优选175-700℃、最优选180-550℃作为入口温度测量的温度。
根据另一方面,提供了包含含镁离子材料的粒料,其中该粒料具有的堆密度为0.10-0.70g/mL,优选0.12-0.65g/mL,更优选0.20-0.60g/mL,最优选0.15-0.50g/mL。
根据一种实施方案,该粒料具有
a)体积粒子尺寸d90为15-500μm,优选20-400μm,最优选30-250μm,通过激光衍射在0.1巴分散压力下干燥测量,和
b)体积中值粒子尺寸d50为5-300μm,优选8-200μm,最优选10-150μm,通过激光衍射在0.1巴分散压力下干燥测量,和
c)体积粒子尺寸d10为1-100μm,优选2-70μm,最优选4-50μm,通过激光衍射在0.1巴分散压力下干燥测量,和/或
d)BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量,和/或
e)球形。
根据另一种实施方案,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
根据又另一种实施方案,该粒料通过本文定义的方法获得。
根据另一个方面,提供了本文定义的粒料在营养产品、农业产品、兽医产品、化妆产品中、优选在干化妆品和/或干皮肤护理组合物中、在家用产品、食物产品、包装产品、个人护理产品中、优选在口腔护理组合物中、在空气处理和水处理中、或者在药物产品中作为赋形剂的用途。
应理解,出于本发明的目的,以下术语具有以下含义。
当术语“包括或包含(comprising)”在本说明书和权利要求书中使用时,其并不排除其他要素。出于本发明的目的,术语“由……组成(consisting of)”被认为是术语“包括或包含(comprising of)”的优选实施方案。如果在下文中定义一个组集(group)包括至少一定数目的实施方案,则这也被理解为公开了一个组集,其优选仅由这些实施方案组成。
在谈论单数名词时使用不定冠词或定冠词如“a”、“an”、或“the”的情况下,这包括了该名词的复数,除非一些情况下另外具体指出。
诸如“可获得(obtainable)”或“可定义(definable)”以及“获得(的)(obtained)”或“定义(的)(defined)”的术语可互换使用。这例如意味着,除非上下文另外明确指出,否则术语“获得(的)”并不意味着指示例如一种实施方案必须通过例如术语“获得(的)”之后的步骤序列来获得,虽然术语“获得(的)”或“定义(的)”总是包括此类限制性理解作为优选实施方案。
根据本发明,该用于生产包含含镁离子材料的粒料的方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,以及
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料。
已经特别发现,根据本发明的方法必须包括均化包含含镁离子材料的水性悬浮液的步骤,以用于获得具有高的堆密度、流动性能和压实性以及高机械稳定性的粒料。
在下文中,将涉及本发明、尤其是上述用于生产包含含镁离子材料的粒料的方法的进一步细节。
本发明的一个要求是:根据步骤a),提供包含含镁离子材料的水性悬浮液。
应理解,术语“含镁离子”是指包含至少38%重量的镁化合物的材料。在一种实施方案中,该含镁离子材料包含基于该材料的总干重计为至少38%重量、优选38-100%重量、更优选38-99.95%重量、例如38-55%重量的镁化合物。在另一种实施方案中,该含镁离子材料包含基于该材料的总干重计为至少85%重量、优选85-100%重量、更优选90-99.95%重量的镁化合物。因此,要指出,该含镁离子材料可进一步包含通常与所用材料类型相关的杂质。例如,该含镁离子材料可进一步包含杂质如含钙离子材料如氢氧化钙、碳酸钙及其混合物。
例如,如果该含镁离子材料包含基于该材料的总干重计为至少38%重量、优选38-100%重量、更优选38-99.95%重量、例如38-45%重量的量的镁化合物,则杂质如含钙离子材料如氢氧化钙、碳酸钙及其混合物以基于该材料的总干重为小于62%重量、优选0-62%重量、更优选0.05-62%重量、例如45-62%重量的量存在。如果该含镁离子材料包含基于该材料的总干重计为至少85%重量、优选85-100%重量、更优选90-99.95%重量的量的镁化合物,则杂质如含钙离子材料如氢氧化钙、碳酸钙及其混合物以基于该材料的总干重为小于15%重量且最优选0.05-10%重量的量存在。还应理解,该含镁离子材料可以是包含钙和镁离子的矿物相,例如白云石(MgCa(CO3)2)。
该含镁离子材料可以是天然存在的或合成的含镁离子材料。
根据本发明的一种实施方案,该天然存在的含镁离子材料可以通过干研磨获得。根据本发明的另一种实施方案,该天然存在的含镁离子材料可以通过湿研磨和任选的后续干燥来获得。
通常,研磨步骤可例如在使得粉碎主要由使用辅助体冲击产生的条件下,用任何传统研磨装置进行,也即在以下的一种或多种中进行:球磨机、棒磨机、振动研磨机、轧碎机、离心冲击研磨机、立式珠磨机、磨碎机、销棒粉碎机、锤磨机、粉磨机、撕碎机、去块机、切割机(knife cutter)或本领域技术人员已知的其它此类设备。在含镁离子材料通过湿研磨获得的情况下,研磨步骤可在使得发生自体研磨的条件下和/或通过水平球磨和/或本领域技术人员已知的其它此类方法来进行。由此获得的经湿加工的研磨的含镁离子材料可通过众所周知的方法,例如通过絮凝、过滤或强制蒸发(在干燥之前)来洗涤并脱水。后续干燥步骤可在单一步骤(例如喷雾干燥)中进行,或者在至少两个步骤中进行。还常见地,这种矿物材料进行选矿步骤(例如浮选、漂白或磁性分离步骤)以去除杂质。
本发明含义中的合成的含镁离子材料可通过本领域众所周知的方法获得。例如,US1361324、US935418、GB548197和GB544907一般性地描述了形成碳酸氢镁(通常被描述为“Mg(HCO3)2”)的水溶液,然后通过碱(例如氢氧化镁)的作用将其转化形成水菱镁矿。本领域所述的其他方法建议制备同时含有水菱镁矿和氢氧化镁的组合物,其中将氢氧化镁与水混合以形成悬浮液,该悬浮液进一步与二氧化碳和碱性水溶液接触以形成相应的混合物;参见例如US5979461。EP0526121描述了一种由碳酸钙和碳酸镁氢氧化物组成的钙-镁碳酸盐复合材料及其制备方法。此外,GB594262涉及一种用于处理含氧化镁材料(例如镁和钙碳酸盐材料)的方法和设备,以通过受控碳酸化来获得离散和分离形式的相应碳酸盐,以使得可以通过机械手段分离镁和钙碳酸盐,并在分离的产品中实现特殊用途。US2007194276描述了一种还原性漂白矿物浆料的方法,包括在矿物浆料中加入有效量的甲脒亚磺酸(FAS)和有效量的硼氢化物以还原性漂白该矿物浆料。
例如,该含镁离子材料涵盖了天然存在的或合成的含镁离子材料。
特别地,步骤a)的含镁离子材料选自含氢氧化镁材料、含碳酸镁材料、含氧化镁材料及其混合物。优选地,步骤a)的含镁离子材料是含碳酸镁材料。
因此,步骤a)的含镁离子材料可选自水镁石(Mg(OH)2),方镁石(MgO),白云石(CaMg(CO3)2),无水碳酸镁或菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),纤菱镁矿(Mg2(CO3)(OH)2·3H2O),球碳镁石(Mg5(CO3)4(OH)2·5H2O),异水菱镁矿(Mg5(CO3)4(OH)2·5H2O),镁白孔雀石(Mg2(CO3)(OH)2·0.5H2O),水碳镁石(MgCO3·2H2O),多水菱镁矿(MgCO3·5H2O),白云质碳酸盐和三水菱镁矿(MgCO3·3H2O)。
然而,该含镁离子材料优选为含碳酸镁材料,选自白云石(CaMg(CO3)2),无水碳酸镁或菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),纤菱镁矿(Mg2(CO3)(OH)2·3H2O),球碳镁石(Mg5(CO3)4(OH)2·5H2O),异水菱镁矿(Mg5(CO3)4(OH)2·5H2O),镁白孔雀石(Mg2(CO3)(OH)2·0.5H2O),水碳镁石(MgCO3·2H2O),多水菱镁矿(MgCO3·5H2O),白云质碳酸盐和三水菱镁矿(MgCO3·3H2O)。
在本发明的含义中,术语“白云质碳酸盐(dolocarbonate)”是指包含在初级粒子水平上团聚的镁矿物、优选水菱镁矿(Mg5(CO3)4(OH)2·4H2O)以及碳酸钙的复合材料。这样的白云质碳酸盐例如描述于WO2013139957A1和WO2015039994A1中,这些文献因此通过引用并入本文。
优选地,该含镁离子材料涵盖了天然存在的或合成的含镁离子材料,选自方镁石(MgO),无水碳酸镁或菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),三水菱镁矿(MgCO3·3H2O),白云石(CaMg(CO3)2),白云质碳酸盐及其混合物。例如,该含镁离子材料包含天然存在的或合成的碳酸镁,选自无水碳酸镁或菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),三水菱镁矿(MgCO3·3H2O),白云石(CaMg(CO3)2),白云质碳酸盐及其混合物,其量为至少80%重量,更优选至少85%重量,甚至更优选85-100%重量,最优选90-99.95%重量,基于该材料的总干重计。
例如,该含镁离子材料包含方镁石(MgO),无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2)或水菱镁矿(Mg5(CO3)4(OH)2·4H2O)或三水菱镁矿(MgCO3·3H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)或三水菱镁矿(MgCO3·3H2O),或天然存在的无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2)。例如,该含镁离子材料包含水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)。在一种实施方案中,该含镁离子材料包含无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2)或水菱镁矿(Mg5(CO3)4(OH)2·4H2O)或三水菱镁矿(MgCO3·3H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)或三水菱镁矿(MgCO3·3H2O),或天然存在的无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2),其量为至少80%重量,更优选至少85%重量,甚至更优选85-100%重量,最优选90-99.95%重量,基于该材料的总干重计。
优选地,该含镁离子材料包含水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),其量为至少80%重量,更优选至少85%重量,甚至更优选85-100%重量,最优选90-99.95%重量,基于该材料的总干重计。
在一种实施方案中,该含镁离子材料由以下物质组成:无水碳酸镁或菱镁矿(MgCO3)和/或白云石(CaMg(CO3)2),例如天然存在的无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2)。
在一种替代实施方案中,该含镁离子材料由以下物质组成:水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)。
在一种实施方案中,步骤a)的含镁离子材料是水菱镁矿,例如天然或合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)。优选地,步骤a)的含镁离子材料是合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)。
应理解,该含镁离子材料优选以不在纳米尺寸范围内的粒子的形式提供。
通常,该含镁离子材料具有的体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定。
额外地或替代地,该含镁离子材料具有的体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
因此,该镁离子材料具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
例如,该含镁离子材料包含方镁石(MgO),无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2)或水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),或天然存在的无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2),并且具有的体积中值粒子尺寸(d50)为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸(d98)为10-40μm,通过激光衍射确定。
优选地,该含镁离子材料包含水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),并且具有的体积中值粒子尺寸(d50)为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸(d98)为10-40μm,通过激光衍射确定。
在一种实施方案中,该含镁离子材料包含方镁石(MgO),无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2)或水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),或天然存在的无水碳酸镁或菱镁矿(MgCO3)或白云石(CaMg(CO3)2),其量为至少80%重量,更优选至少85%重量,甚至更优选85-100%重量,最优选90-99.95%重量,基于该材料的总干重计,并且具有的体积中值粒子尺寸(d50)为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸(d98)为10-40μm,通过激光衍射确定。
优选地,该含镁离子材料包含水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),其量为至少80%重量,更优选至少85%重量,甚至更优选85-100%重量,最优选90-99.95%重量,基于该材料的总干重计,并且具有的体积中值粒子尺寸(d50)为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸(d98)为10-40μm,通过激光衍射确定。
在整个本文件中,含镁离子材料的“粒子尺寸”通过其基于体积的粒子尺寸分布来描述。使用配备有Hydro LV系统的Malvern Mastersizer3000激光衍射系统(MalvernInstruments Plc.,英国)评价体积确定的中值粒子尺寸d50(或d50(vol))和体积确定的顶切粒子尺寸d98(或d98(vol))。d50(vol)或者d98(vol)值表示的直径值使得以体积计分别为50%或者98%的粒子具有小于该值的直径。将粉末悬浮在0.1%重量的Na4O7P2溶液中。将10mL的0.1%重量Na4O7P2添加到Hydro LV槽中,然后引入样品浆料,直到获得10-20%的遮蔽度。每个用红光和蓝光进行10s的测量。对于原始数据的分析,利用了使用Mie理论的非球形粒子尺寸的模型,并且假设粒子折射率为1.57,密度为2.70g/cm3,吸收指数为0.005。方法及仪器为本领域技术人员已知并且常见地用于确定填料和颜料的粒子尺寸分布。
额外地或替代地,该含镁离子材料具有的BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
本申请通篇中使用的材料的“比表面积”(以m2/g表示)可通过Brunauer EmmettTeller(BET)法使用氮气作为吸附气体并且通过使用Micromeritics的ASAP 2460仪器来确定。该方法为本领域技术人员所熟知,并在ISO 9277:2010中定义。在测量之前,将样品在150℃下在真空条件下调理60分钟。
额外地或替代地,该含镁离子材料具有的粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
使用Micromeritics Autopore V 9620汞孔率计,使用汞侵入孔隙率测定法(mercury intrusion porosimetry)测量结果测量比孔容,所述汞孔率计具有最大施加汞压为414MPa(60 000psi),等效于0.004μm(~nm)的拉普拉斯喉径。在每个压力步骤使用的平衡时间是20秒。将样品材料密封在5cm3室的粉末透度计中用于分析。使用软件Pore-Comp(Gane,P.A.C.,Kettle,J.P.,Matthews,G.P.和Ridgway,C.J.,“Void Space Structure ofCompressible Polymer Spheres and Consolidated Calcium Carbonate Paper-CoatingFormulations”,Industrial and Engineering Chemistry Research,35(5),1996年,第1753-1764页),针对汞压缩、透度计膨胀和样品材料压缩来校正数据。
在累积侵入数据中见到的总孔体积可被分成两个区域,其中从214μm降至约1-4μm的侵入数据显示具有强烈贡献的任何附聚结构之间的样品的粗填充。在这些直径之下的是粒子自身的精细粒子间填充。如果它们也具有粒子内孔,则此区域显现双峰,并且通过获取由汞侵入比峰转折点更细(即比双峰拐点更细)的孔的比孔容,因而定义比粒子内孔体积。这三个区域的总和给出了粉末的总全部孔体积,但强烈地取决于原始样品压实/在分布的粗孔末端处的粉末的沉降。
通过获取累积侵入曲线的第一导数,揭示了基于等效拉普拉斯直径的孔尺寸分布,其必然包括孔屏蔽。微分曲线清楚地显示了粗附聚孔结构区域、粒子间孔区域和粒子内孔区域(如果存在的话)。已知粒子内孔直径范围,则可以从总孔体积中减去剩余粒子间和附聚体间孔体积,以给出在每单位质量孔体积(比孔容)方面的单独的内部孔的希望的孔体积。当然,相同的减法原理也适用于分离任何感兴趣的其它孔尺寸区域。
因此,该含镁离子材料具有
a)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量,和
b)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
在一种实施方案中,该含镁离子材料因而具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
例如,该含镁离子材料是水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
优选地,该含镁离子材料因而具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
例如,该含镁离子材料是水菱镁矿(Mg5(CO3)4(OH)2·4H2O),例如合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
应理解,该含镁离子材料优选为含碳酸镁材料。
该含碳酸镁材料可以是天然存在的或合成的含碳酸镁材料。
例如,该含碳酸镁材料涵盖了天然存在的或合成的碳酸镁,选自菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),纤菱镁矿(Mg2(CO3)(OH)2·3H2O),球碳镁石(Mg5(CO3)4(OH)2·5H2O),异水菱镁矿(Mg5(CO3)4(OH)2·5H2O),镁白孔雀石(Mg2(CO3)(OH)2·0.5H2O),水碳镁石(MgCO3·2H2O),多水菱镁矿(MgCO3·5H2O),三水菱镁矿(MgCO3·3H2O),白云质碳酸盐及其混合物。
优选地,该含碳酸镁材料涵盖了合成的含碳酸镁材料,选自菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),纤菱镁矿(Mg2(CO3)(OH)2·3H2O),球碳镁石(Mg5(CO3)4(OH)2·5H2O),异水菱镁矿(Mg5(CO3)4(OH)2·5H2O),镁白孔雀石(Mg2(CO3)(OH)2·0.5H2O),水碳镁石(MgCO3·2H2O),多水菱镁矿(MgCO3·5H2O),三水菱镁矿(MgCO3·3H2O),白云质碳酸盐及其混合物。
在一种实施方案中,该含碳酸镁材料包含合成水菱镁矿(Mg5(CO3)4(OH)2·4H2O)。优选地,该含碳酸镁材料包含合成水菱镁矿(Mg5(CO3)4(OH)2·4H2O),其量为至少80%重量,更优选至少85%重量,甚至更优选85-100%重量,最优选90-99.95%重量,基于该材料的总干重计。
要指出,该合成水菱镁矿也可被称为沉淀水菱镁矿。
该含碳酸镁材料是颗粒状材料的形式,并且可具有如要生产的产品类型中所涉及的材料常规使用的粒子尺寸分布。通常,优选地,该含碳酸镁材料具有的体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定。
额外地或替代地,该含碳酸镁材料具有的体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
因此,该含碳酸镁材料优选具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
在一种实施方案中,该含碳酸镁材料具有的体积中值粒子尺寸d50为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸d98为10-40μm,通过激光衍射确定。
例如,该含碳酸镁材料是合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),并且具有的体积中值粒子尺寸d50为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸d98为10-40μm,通过激光衍射确定。
额外地或替代地,该含碳酸镁材料具有的BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
额外地或替代地,如果该含碳酸镁材料具有高的粒子内侵入式比孔容则是特别有利的。例如,优选地,该含碳酸镁材料具有0.9-2.3cm3/g的粒子内侵入式比孔容,由汞孔隙率测定法测量结果计算。在一种实施方案中,该含碳酸镁材料具有的粒子内侵入式比孔容为1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
优选地,该含碳酸镁材料具有17-60m2/g的比表面积,根据ISO 9277:2010使用氮气和BET法测量,以及1.5-2.0cm3/g的粒子内侵入式比孔容,由汞孔隙率测定法测量结果计算。
根据一种实施方案,该含碳酸镁材料具有
a)比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量,和
b)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
优选地,该含碳酸镁材料具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
在一种实施方案中,步骤a)的含镁离子材料是经表面反应的含碳酸镁材料。
特别地,该经表面反应的含碳酸镁材料通过用一种或多种化合物处理含碳酸镁材料的表面而获得,所述化合物选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或者其相应的盐。
因此,应指出,该经表面反应的含碳酸镁材料通过用一种化合物处理含碳酸镁材料的表面而获得。替代地,该经表面反应的含碳酸镁材料通过用两种或更多种化合物处理含碳酸镁材料的表面而获得。例如,该经表面反应的含碳酸镁材料通过用两种或三种或四种化合物(如两种化合物)处理含碳酸镁材料的表面而获得。
在本发明的一种实施方案中,该经表面反应的含碳酸镁材料通过用两种化合物处理含碳酸镁材料的表面而获得。
根据一种实施方案,该经表面反应的含碳酸镁材料通过用硫酸处理含碳酸镁材料的表面而获得。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用硫酸的盐如硫酸的碱金属盐处理含碳酸镁材料的表面而获得。例如,硫酸的碱金属盐是硫酸钠或硫酸钾,优选硫酸钠。
额外地或替代地,该经表面反应的含碳酸镁材料通过用磷酸处理含碳酸镁材料的表面而获得。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用磷酸的盐如磷酸的碱金属盐处理含碳酸镁材料的表面而获得。例如,磷酸的碱金属盐是磷酸钠或磷酸钾,优选磷酸钠。
额外地或替代地,该经表面反应的含碳酸镁材料通过用碳酸处理含碳酸镁材料的表面而获得。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用碳酸的盐如碳酸的碱金属盐处理含碳酸镁材料的表面而获得。例如,碳酸的碱金属盐是碳酸钠或碳酸钾,优选碳酸钠。
额外地或替代地,该经表面反应的含碳酸镁材料通过用含有至多六个碳原子的羧酸处理含碳酸镁材料的表面而获得。
该含有至多六个碳原子的羧酸优选为脂族羧酸,并且可选自一种或多种线性链、支化链、饱和、不饱和和/或脂环族羧酸。优选地,该含有至多六个碳原子的羧酸是一元羧酸,即该含有至多六个碳原子的羧酸的特征在于存在单个羧基。所述羧基优选位于碳骨架的末端。
在本发明的一种实施方案中,该含有至多六个碳原子的羧酸优选选自甲酸、乙酸、丙酸、乳酸、丁酸、戊酸、己酸及其混合物。更优选地,该含有至多六个碳原子的羧酸选自甲酸、乙酸、丙酸、乳酸、丁酸及其混合物。
例如,该含有至多六个碳原子的羧酸选自甲酸、乙酸、丙酸、乳酸及其混合物。优选地,该含有至多六个碳原子的羧酸选自乙酸、丙酸及其混合物。
在一种实施方案中,该含有至多六个碳原子的羧酸是乙酸。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用该含有至多六个碳原子的羧酸的盐如该含有至多六个碳原子的羧酸的碱金属盐处理含碳酸镁材料的表面而获得。例如,该含有至多六个碳原子的羧酸的碱金属盐是甲酸、乙酸、丙酸、乳酸及其混合物的钠盐或钾盐,优选钠盐。
额外地或替代地,该经表面反应的含碳酸镁材料通过用含有至多六个碳原子的二羧酸和/或三羧酸处理含碳酸镁材料的表面而获得,其中羧酸基团通过0-4个间断碳原子的链连接。
该含有至多六个碳原子的二羧酸的特征在于存在两个羧基。所述羧基优选置于碳骨架的每一端,条件是羧酸基团通过0-4个间断碳原子的链连接。
在本发明的一种实施方案中,该含有至多六个碳原子的二羧酸优选选自草酸、丙二酸、马来酸、琥珀酸、酒石酸、戊二酸、己二酸、富马酸及其混合物。更优选地,该含有至多六个碳原子的二羧酸选自草酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用该含有至多六个碳原子的二羧酸的盐如该含有至多六个碳原子的二羧酸的碱金属盐处理含碳酸镁材料的表面而获得。例如,该含有至多六个碳原子的二羧酸的盐是草酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸和/或富马酸的钠盐,优选草酸、马来酸,丙二酸和/或富马酸的钠盐。应理解,该含有至多六个碳原子的二羧酸的盐可以是二羧酸的一元盐或二元盐。
该含有至多六个碳原子的三羧酸的特征在于存在三个羧基。两个羧基置于碳骨架的每一端,条件是两个羧酸基团通过0-4个间断碳原子的链连接。
在本发明的一种实施方案中,该含有至多六个碳原子的三羧酸优选选自柠檬酸、异柠檬酸、乌头酸及其混合物。更优选地,该含有至多六个碳原子的三羧酸选自柠檬酸和/或异柠檬酸。
最优选地,该含有至多六个碳原子的三羧酸是柠檬酸。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用该含有至多六个碳原子的三羧酸的盐如该含有至多六个碳原子的三羧酸的碱金属盐处理含碳酸镁材料的表面而获得。例如,该含有至多六个碳原子的三羧酸的碱金属盐是柠檬酸钠或柠檬酸钾,优选柠檬酸钠。应理解,该含有至多六个碳原子的三羧酸的盐可以是三羧酸的一元盐、二元盐或三元盐。例如,该含有至多六个碳原子的三羧酸的盐可以是柠檬酸的一元盐、二元盐或三元盐,例如柠檬酸一钠、柠檬酸二钠或柠檬酸三钠。
在一种实施方案中,该经表面反应的含碳酸镁材料通过用一种或多种化合物处理含碳酸镁材料的表面而获得,该化合物是二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物。替代地,该经表面反应的含碳酸镁材料通过用一种或多种化合物处理含碳酸镁材料的表面而获得,该化合物是二羧酸和三羧酸的钠盐,其中羧酸基团通过0-4个间断碳原子的链连接,所述酸优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物。
优选地,该经表面反应的含碳酸镁材料通过用磷酸或磷酸的碱金属盐如磷酸钠、更优选磷酸的碱金属盐如磷酸钠处理含碳酸镁材料的表面而获得。替代地,该经表面反应的含碳酸镁材料通过用硫酸或硫酸的碱金属盐如硫酸钠、更优选硫酸钠处理含碳酸镁材料的表面而获得。替代地,该经表面反应的含碳酸镁材料通过用柠檬酸或柠檬酸的碱金属盐如柠檬酸钠、更优选柠檬酸的碱金属盐如柠檬酸钠处理含碳酸镁材料的表面而获得。
鉴于以上所述,该含碳酸镁材料的表面优选包含一种或多种化合物,所述化合物选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或其相应的盐和/或其反应产物。
本发明含义中的术语“反应产物”是指通过使该含碳酸镁材料的表面与一种或多种化合物接触而获得的产物,所述化合物选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或其相应的盐。所述反应产物在所施加的一种或多种化合物与位于该含碳酸镁材料的表面处的反应性分子之间形成。
应理解,该经表面反应的含碳酸镁材料优选通过用该一种或多种化合物或其相应盐以基于该含碳酸镁材料的总干重计为0.1-20%重量的量处理含碳酸镁材料的表面而获得。例如,该经表面反应的含碳酸镁材料优选通过用该一种或多种化合物或其相应盐以基于该含碳酸镁材料的总干重计为0.1-15%重量的量处理含碳酸镁材料的表面而获得。优选地,该经表面反应的含碳酸镁材料优选通过用该一种或多种化合物或其相应盐以基于该含碳酸镁材料的总干重计为0.5-15%重量的量处理含碳酸镁材料的表面而获得。
通常,该经表面反应的含碳酸镁材料可通过适合于在填料材料如含碳酸镁材料的表面上获得一种或多种化合物的处理层的任何已知方法来制备。
例如,该经表面反应的含碳酸镁材料通过包括至少以下步骤的方法获得:
i)提供含碳酸镁材料,
ii)提供一种或多种化合物,选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或其相应的盐,以及
iii)在一个或多个步骤中,在混合下用步骤b)的一种或多种化合物或其相应的盐处理步骤a)的含碳酸镁材料的表面,使得通过该一种或多种化合物或其相应的盐与所述含碳酸镁材料的表面实现反应。
例如,该经表面反应的含碳酸镁材料以干法制备,例如通过在不使用溶剂的情况下将该一种或多种化合物施加到含碳酸镁材料的表面上来制备。如果该一种或多种化合物是固态的,则可以加热该一种或多种化合物以提供液态的它们,从而确保该一种或多种化合物在含碳酸镁材料的表面上基本均匀的分布。
替代地,该经表面反应的含碳酸镁材料以湿法制备,例如通过将该一种或多种化合物溶解在溶剂中并将混合物施加到含碳酸镁材料的表面上来制备。任选地,可以加热包含该溶剂和该一种或多种化合物的混合物。如果该一种或多种化合物溶解在溶剂中,则该溶剂优选为有机溶剂,优选选自甲苯、丙酮和乙醇。
通常,用该一种或多种化合物或其相应的盐处理含碳酸镁材料的表面的步骤可通过任何适合于实现该一种或多种化合物的基本均匀分布并因此在含碳酸镁材料表面上的反应的方法来进行。因此,将该一种或多种化合物与含碳酸镁材料混合,优选搅拌或摇动,以促进和加速该经表面反应的含碳酸镁材料的制备,例如通过使用混合装置、喷涂机或包封工艺来进行。如果使用溶剂,则可优选在真空下干燥所获得的经表面反应的含碳酸镁材料以去除挥发性组分。
在干法和湿法中,用该一种或多种化合物或其相应的盐处理含碳酸镁材料的表面以使得通过该一种或多种化合物或其相应的盐与所述含碳酸镁材料的表面实现反应的步骤可在单个步骤或至少两个步骤中进行。
根据本发明的一种实施方案,该经表面反应的含碳酸镁材料因而通过以下的一种或多种方法制备:
(i)干处理,即用纯形式的该一种或多种化合物处理含碳酸镁材料的表面,优选在混合装置中或通过使用喷涂机来进行;
(ii)湿处理,即用溶解在溶剂中的该一种或多种化合物处理含碳酸镁材料的表面,任选地在加热下,优选在混合装置中或通过使用喷涂机来进行;或者
(iii)熔融干处理,即在加热的混合器(例如流化床混合器)中用纯形式的该一种或多种化合物的熔体处理含碳酸镁材料的表面。
所获得的经表面反应的含碳酸镁材料优选具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定。根据本发明的另一种实施方案,该经表面反应的含碳酸镁材料是粒子的形式,该粒子具有体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
因此,该经表面反应的含碳酸镁材料具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
在一种实施方案中,该经表面反应的含碳酸镁材料具有体积中值粒子尺寸d50为1.9-10μm,通过激光衍射确定,并且体积顶切粒子尺寸d98为10-40μm,通过激光衍射确定。
例如,该经表面反应的含碳酸镁材料通过用一种或多种化合物处理合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O)的表面来获得,所述化合物选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团由0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或其相应的盐,并且具有体积中值粒子尺寸d50为1.9-10μm,通过激光衍射确定,以及体积顶切粒子尺寸d98为10-40μm,通过激光衍射确定。
在一种实施方案中,该经表面反应的含碳酸镁材料具有BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
额外地或替代地,该经表面反应的含碳酸镁材料具有粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
例如,该经表面反应的含碳酸镁材料具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
例如,该经表面反应的含碳酸镁材料是经表面反应的合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
如上所述,步骤a)的含镁离子材料以水性悬浮液的形式提供。
优选地,步骤a)的水性悬浮液具有的固体含量为1-40%重量,优选5-35%重量,最优选7-26%重量,基于该水性悬浮物的总重量计。
出于本发明的目的,“悬浮液”或“浆料”是指包含液体(即水性溶剂)和含镁离子材料的粒子的系统,其中该含镁离子材料的粒子以固体形式存在于液体中。该水性悬浮液比形成它的液体更为粘性并且可具有更高的密度。
该“液体”典型地是“水性溶剂”,不排除该水性溶剂包含少量的至少一种水混溶性溶剂。例如,该至少一种水混溶性溶剂优选选自甲醇、乙醇、丙酮、乙腈、四氢呋喃及其混合物。在本发明的一种实施方案中,该液体包含基于该水性溶剂的总重量计为至少80%重量、优选至少90%重量、更优选至少95%重量、甚至更优选至少99%重量的量的水。优选地,该水性溶剂由水组成,即基于该液体的总重量计,水的量为100%重量。
进一步优选地,步骤a)中提供的水性悬浮液在100rpm下在+23℃(±2℃)的温度下具有25-1000mPas的Brookfield粘度,优选在+23℃(±2℃)下具有25-700mPas的Brookfield粘度,更优选在+23℃(±2℃)下具有25-500mPas的Brookfield粘度,并且最优选在+23℃(±2℃)下具有50-300mPas的Brookfield粘度。
根据本方法的步骤b),将步骤a)的包含含镁离子材料的水性悬浮液均化。
本发明含义中的“均化”是指使步骤a)的水性悬浮液中的含镁离子材料的粒子在干燥后在粒料稳定性方面产生更强的聚集体的步骤。
该均化可以通过使用本领域公知的各种方法来进行。
均化设备可以从用于均化目的常规设备中选择。因此,均化设备可选自活塞泵、高剪切装置等。例如,GEA Mechanical Equipment Italia S.p.a.的GEA Ariete NS3055可用于步骤b)中的均化。
替代地,步骤b)中的均化通过研磨进行。步骤b)中的均化可在本领域熟知的研磨或捏合装置中进行。因此,该研磨或捏合装置可选自通常用于研磨目的的卧式和立式研磨机或通常用于捏合目的的捏合机。例如,研磨装置可选自卧式和/或立式搅拌介质磨机,优选立式搅拌介质磨机,卧式和/或立式搅拌珠磨机,例如Dyno KDL珠磨机、Netzsch LabStar或LMZ型磨机或LME型磨机;砂磨机等。例如,捏合装置可选自Sigma-Kneader、行星式混合机等。
可指出,取决于所使用的方法,在要实现的粒子尺寸分布方面可能存在差异。
步骤b)中的均化进行一次或多次。应理解,进行步骤b)的次数主要取决于所使用的压力和在步骤b)中获得的含镁离子材料。本领域技术人员因而可以根据步骤b)期间使用的设备或条件容易地调整进行步骤b)的次数。因此,步骤b)中的均化能够以再循环模式进行。
优选地,步骤b)中的均化进行1-5次,更优选1-3次,即一次、两次或三次,甚至更优选一次或两次。最优选地,步骤b)中的均化进行两次。
应理解,步骤b)中的均化优选通过使用高压均化器来进行。
在一种实施方案中,步骤b)中的均化在50-900巴、优选100-750巴、最优选130-650巴的压力下进行。
额外地或替代地,步骤b)中的均化在5-95℃、优选10-80℃、最优选15-60℃的初始温度下进行。
因此,优选地,步骤b)中的均化在以下条件下进行
a)50-900巴、优选100-750巴、最优选130-650巴的压力,或
b)5-95℃、优选10-80℃、最优选15-60℃的初始温度。
更优选地,步骤b)中的均化在以下条件下进行
a)50-900巴、优选100-750巴、最优选130-650巴的压力,和
b)5-95℃、优选10-80℃、最优选15-60℃的初始温度。
优选地,步骤b)中获得的水性悬浮液具有基于步骤b)中水性悬浮液的总重量计的固体含量为1-40%重量,优选5-35%重量,最优选7-26%重量,例如10-25%重量或15-25%重量。
应理解,与要经历步骤b)的水性悬浮液相比,步骤b)中的均化可导致水性悬浮物中固体含量的增加。例如,在均化步骤b)中获得的水性悬浮液可具有比要经历步骤b)的水性悬浮液的固体含量高至少1%、更优选至少2%、最优选至少3%、例如3%-4%的固体含量。如果步骤b)在均化器中进行,这尤其适用。
如果步骤b)通过研磨进行,则在均化步骤b)中获得的水性悬浮液优选具有比要经历步骤b)的水性悬浮液的固体含量高至多3%、更优选至多2%、最优选至多1%的固体含量。
应理解,通过研磨的均化优选在10-125kWh/吨干产品、优选25-100kWh/吨干产品的比能下进行。
额外地或替代地,通过研磨的均化在5-95℃、优选10-80℃、最优选15-60℃的初始温度下进行。
因此,优选地,在步骤b)中通过研磨进行的均化在以下条件下进行:
a)10-125kWh/吨干产品、优选25-100kWh/吨干产品的比能;或
b)5-95℃、优选10-80℃、最优选15-60℃的初始温度。
更优选地,在步骤b)中通过研磨进行的均化在以下条件下进行:
a)10-125kWh/吨干产品、优选25-100kWh/吨干产品的比能;和
b)5-95℃、优选10-80℃、最优选15-60℃的初始温度。
在一种优选实施方案中,步骤b)中的均化通过研磨进行。
在一种实施方案中,在步骤b)之前和/或期间和/或之后添加至少一种崩解剂。优选地,该至少一种崩解剂在步骤b)之前、期间或之后添加,更优选在步骤b)之前或之后添加。最优选地,在步骤b)之后添加该至少一种崩解剂。
在本发明的一种实施方案中,该至少一种崩解剂包含一种崩解剂,优选由一种崩解剂组成。替代地,该至少一种崩解剂包含两种或更多种崩解剂,优选由两种或更多种崩解剂组成。例如,该至少一种崩解剂包含两种或三种崩解剂,优选由两种或三种崩解剂组成。
优选地,该至少一种崩解剂包含一种崩解剂,优选由一种崩解剂组成。
要指出,可用于本发明方法的崩解剂通常是造粒领域中公知的那些。
要指出,任何已知为崩解剂或可起到崩解剂作用的化合物都可被用在本发明的方法中。
在一种优选实施方案中,该至少一种崩解剂可选自交联羧甲基纤维素钠、改性纤维素胶、不溶性交联聚乙烯吡咯烷酮、淀粉、改性淀粉、淀粉羟乙酸盐如淀粉羟乙酸钠、微晶纤维素、预糊化淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、N-乙烯基-2-吡咯烷酮的均聚物、烷基纤维素酯、羟烷基纤维素酯、羧基烷基纤维素酯、藻酸、微晶纤维素及其多晶型、离子交换树脂、树胶、甲壳素、壳聚糖、粘土、结冷胶、交联泼拉克林共聚物、琼脂、明胶、糊精、丙烯酸聚合物、羧甲基纤维素钠/钙、邻苯二甲酸羟丙基甲基纤维素、虫胶、泡腾混合物如碳酸氢盐组合一种或多种酸如柠檬酸或酒石酸、或其混合物。优选地,该至少一种崩解剂是交联羧甲基纤维素钠。该至少一种崩解剂也可以是超级崩解剂。可用于本发明方法的超级崩解剂通常是本领域已知的那些。示例性的超级崩解剂包括但不限于交联羧甲基纤维素钠、不溶性交联聚乙烯吡咯烷酮、淀粉羟乙酸钠及其混合物。
如果在步骤b)之前和/或期间和/或之后添加至少一种崩解剂,则基于该含镁离子材料的总干重计,优选以0.1-10%重量、优选0.3-10%重量%、更优选0.5-8%重量、最优选1至约5%重量的量添加该至少一种崩解剂。
该至少一种崩解剂可以以干燥形式或以乳液、分散体或溶液的形式添加。
因此,在一种实施方案中,用于生产包含含镁离子材料的粒料的方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料,以及
d)在步骤b)之前和/或期间和/或之后将至少一种崩解剂添加到水性悬浮液中。
在一种优选实施方案中,用于生产包含含镁离子材料的粒料的方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)通过研磨均化步骤a)的包含含镁离子材料的水性悬浮液,
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料,以及
d)在步骤b)之前和/或期间和/或之后将至少一种崩解剂添加到水性悬浮液中。
替代地,该方法可包括在步骤b)之前和/或期间和/或之后机械和/或物理崩解包含含镁离子材料的水性悬浮液的步骤d)。
这种机械和/或物理崩解可通过本领域技术人员已知的适合于这种目的任何方法进行。例如,机械和/或物理崩解步骤d)可通过超声波探针等进行。
因此,在一种实施方案中,用于生产包含含镁离子材料的粒料的方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料,以及
d)在步骤b)之前和/或期间和/或之后机械和/或物理崩解包含含镁离子材料的水性悬浮液。
在一种优选实施方案中,用于生产包含含镁离子材料的粒料的方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)通过研磨均化步骤a)的包含含镁离子材料的水性悬浮液,
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料,以及
d)在步骤b)之前和/或期间和/或之后机械和/或物理崩解包含含镁离子材料的水性悬浮液。
应理解,可以在步骤b)之前和/或期间和/或之后、优选在步骤b)之前或之后、最优选在步骤b)之后添加适用于改善口感、适口性或受控释放的其他添加剂如多元醇如甘露醇、山梨醇等;羧甲基纤维素、水胶体如纤维素纤维(cellulos)及其衍生物、微晶纤维素等;糖或研磨碳酸钙(GCC)。
这样的添加剂如果添加的话则优选以基于该含镁离子材料的总干重计为0.3-40%重量、优选0.5-30%重量、更优选1至约25%重量的量添加。
根据本发明的步骤c),借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料。
喷雾干燥设备可以从用于喷雾干燥目的的常规使用的设备中选择。因此,喷雾干燥器可选自旋转雾化器、喷泉式喷嘴、双流体喷嘴、压力喷嘴、组合喷嘴等。优选地,喷雾干燥步骤c)通过使用旋转雾化器或双流体喷嘴来进行。如果均化步骤b)通过研磨进行,则喷雾干燥器可选自用于喷雾干燥的常规使用的那些,例如喷雾干燥器可选自旋转雾化器、喷泉式喷嘴、双流体喷嘴、压力喷嘴、组合喷嘴等。关于喷泉式喷嘴,要指出,它也可被称为以喷泉(或并流)模式运行的压力喷嘴。在一种实施方案中,均化步骤b)通过研磨进行,喷雾干燥步骤c)通过使用旋转雾化器进行。应理解,对于不同的喷雾干燥技术要设定不同的条件以获得所需的粒料。而本领域技术人员知道如何使这些条件适应不同的喷雾干燥技术。
例如,如果使用压力喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.1-300巴,优选1-100巴,更优选1至<50巴,最优选1-25巴,和/或
b)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
在一种实施方案中,如果使用压力喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.1-300巴,优选1-100巴,更优选1至<50巴,最优选1-25巴,或
b)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
优选地,如果使用压力喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.1-300巴,优选1-100巴,更优选1至<50巴,最优选1-25巴,和
b)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
在一种实施方案中,如果使用双流体喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.1-300巴,优选1-100巴,更优选1至<50巴,最优选1-25巴,例如7-25巴,和/或
b)孔口直径为0.8-1.8mm,优选0.9-1.6mm,最优选1.05-1.5mm,和/或
c)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃,和/或
d)到喷嘴的空气压力为1-7巴,优选1.5-6.5巴,最优选2-6巴。
例如,如果使用双流体喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.1-300巴,优选1-100巴,更优选1至<50巴,最优选1-25巴,例如7-25巴,或
b)孔口直径为0.8-1.8mm,优选0.9-1.6mm,最优选1.05-1.5mm,或
c)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃,或
d)到喷嘴的空气压力为1-7巴,优选1.5-6.5巴,最优选2-6巴。
替代地,如果使用双流体喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.1-300巴,优选1-100巴,更优选1至<50巴,最优选1-25巴,例如7-25巴,和
b)孔口直径为0.8-1.8mm,优选0.9-1.6mm,最优选1.05-1.5mm,和
c)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃,和
d)到喷嘴的空气压力为1-7巴,优选1.5-6.5巴,最优选2-6巴。
应理解,双流体喷嘴在本领域中是众所周知的,并且包括例如丹麦GEA-Niro的组合喷嘴。
在一种实施方案中,如果使用旋转雾化器,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.5-8巴,优选1-6.5巴,最优选1-4.5巴,例如1.5-4.5巴,和/或
b)转轮的速度≤11000,优选8000-11000rpm,更优选9000-10000rpm(在d=150mm的轮径和/或73m/s的速度下),和/或
c)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
例如,如果使用旋转雾化器,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.5-8巴,优选1-6.5巴,最优选1-4.5巴,例如1.5-4.5巴,或
b)转轮的速度≤11000,优选8000-11000rpm,更优选9000-10000rpm(在d=150mm的轮径和/或73m/s的速度下),或
c)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
替代地,如果使用旋转雾化器,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为0.5-8巴,优选1-6.55巴,最优选1-4.5巴,例如1.5-4.5巴,和
b)转轮的速度≤11000,优选8000-11000rpm,更优选9000-10000rpm(在d=150mm的轮径和/或73m/s的速度下),和
c)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
在一种实施方案中,如果使用喷泉式喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为8-60巴,优选10-25巴,最优选11-18巴,和/或
b)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
例如,如果使用喷泉式喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为8-60巴,优选10-25巴,最优选11-18巴,或
b)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
替代地,如果使用喷泉式喷嘴,则步骤c)中的喷雾干燥在以下条件下进行:
a)进料压力为8-60巴,优选10-25巴,最优选11-18巴,和
b)作为入口温度测量的温度为120-950℃,优选175-700℃,最优选180-550℃。
在步骤c)中获得的粒料优选为干燥形式,即自由流动的形式。
术语“干(或干燥)”粒料被理解为是相对于粒料重量计具有小于4%重量的水的材料。可采用根据ISO 787-2的方法,在干燥室中将粒料加热至105℃来确定水的百分比。
通过本发明方法获得的粒料具有有利的堆密度。因此,本发明在另一个方面中涉及包含含镁离子材料的粒料,其中该粒料具有0.1-0.70g/mL的堆密度。优选地,该粒料包含含镁离子材料,其中该粒料具有0.1-0.70g/mL的堆密度。更优选地,该粒料包含含碳酸镁材料,其中该粒料具有0.1-0.70g/mL的堆密度。最优选地,该粒料包含经表面反应的含碳酸镁材料,其中该粒料具有0.1-0.70g/mL的堆密度。例如,该粒料包含经表面反应的合成(或沉淀)水菱镁矿(Mg5(CO3)4(OH)2·4H2O),其中该粒料具有0.1-0.70g/mL的堆密度。
例如,该粒料具有的堆密度为0.12-0.65g/mL,更优选0.20-0.60g/mL,最优选0.15-0.50g/mL。
应理解,该粒料优选具有可根据所使用的方法进行调节的非常特定的粒子尺寸分布。
特别地,该粒料具有
a)通过激光衍射在0.1巴分散压力下干燥测量的体积粒子尺寸d90为15-500μm,和
b)通过激光衍射在0.1巴分散压力下干燥测量的体积中值粒子尺寸d50为5-300μm,和
c)通过激光衍射在0.1巴分散压力下干燥测量的体积粒子尺寸d10为1-100μm。
优选地,该粒料具有
a)通过激光衍射在0.1巴分散压力下干燥测量的体积粒子尺寸d90为20-400μm,和
b)通过激光衍射在0.1巴分散压力下干燥测量的体积中值粒子尺寸d50为8-200μm,和
c)通过激光衍射在0.1巴分散压力下干燥测量的体积粒子尺寸d10为2-70μm。
最优选地,该粒料具有
a)通过激光衍射在0.1巴分散压力下干燥测量的体积粒子尺寸d90为30-250μm,和
b)通过激光衍射在0.1巴分散压力下干燥测量的体积中值粒子尺寸d50为10-150μm,和
c)通过激光衍射在0.1巴分散压力下干燥测量的体积粒子尺寸d10为4-50μm。
此外,该粒料优选具有BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量。
因此,该粒料优选具有
a)体积粒子尺寸d90为15-500μm,优选20-400μm,最优选30-250μm,通过激光衍射在0.1巴分散压力下干燥测量,和
b)体积中值粒子尺寸d50为5-300μm,优选8-200μm,最优选10-150μm,通过激光衍射在0.1巴分散压力下干燥测量,和
c)体积粒子尺寸d10为1-100μm,优选2-70μm,最优选4-50μm,通过激光衍射在0.1巴分散压力下干燥测量,和
d)BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量。
额外地或替代地,该粒料具有球形。本发明含义中的“球形”是指在三维空间中的所有轴上具有几乎相同直径的粒料。
因此,该粒料优选具有
a)体积粒子尺寸d90为15-500μm,优选20-400μm,最优选30-250μm,通过激光衍射在0.1巴分散压力下干燥测量,和
b)体积中值粒子尺寸d50为5-300μm,优选8-200μm,最优选10-150μm,通过激光衍射在0.1巴分散压力下干燥测量,和
c)体积粒子尺寸d10为1-100μm,优选2-70μm,最优选4-50μm,通过激光衍射在0.1巴分散压力下干燥测量,和
d)BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量,和/或
e)球形。
例如,该粒料优选具有
a)体积粒子尺寸d90为15-500μm,优选20-400μm,最优选30-250μm,通过激光衍射在0.1巴分散压力下干燥测量,和
b)体积中值粒子尺寸d50为5-300μm,优选8-200μm,最优选10-150μm,通过激光衍射在0.1巴分散压力下干燥测量,和
c)体积粒子尺寸d10为1-100μm,优选2-70μm,最优选4-50μm,通过激光衍射在0.1巴分散压力下干燥测量,和
d)BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量,或
e)球形。
替代地,该粒料优选具有
a)体积粒子尺寸d90为15-500μm,优选20-400μm,最优选30-250μm,通过激光衍射在0.1巴分散压力下干燥测量,和
b)体积中值粒子尺寸d50为5-300μm,优选8-200μm,最优选10-150μm,通过激光衍射在0.1巴分散压力下干燥测量,和
c)体积粒子尺寸d10为1-100μm,优选2-70μm,最优选4-50μm,通过激光衍射在0.1巴分散压力下干燥测量,和
d)BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量,和
e)球形。
还要指出,该粒料显示出有利的稳定性。特别地,与通过相同方法但缺少使包含含镁离子材料的水性悬浮液均化的步骤所获得的粒料相比,所述粒料显示出更高的稳定性。例如,该粒料具有由对于(0.5巴)vs.(0.1巴)来说的比率d50所确定的稳定性为≥15,更优选≥20,甚至更优选≥25,最优选≥30,例如30-90。额外地或替代地,该粒料具有由对于(1.5巴)vs.(0.1巴)来说的比率d50所确定的稳定性为≥5,更优选≥7,甚至更优选≥10,最优选≥12,例如12-90或12-80。
进一步优选地,该粒料具有由对于(0.5巴)vs.(0.1巴)来说的比率d50所确定的稳定性为≥15%,更优选≥20%,甚至更优选≥25%,最优选≥30%,如30-80%。额外地或替代地,该粒料具有由对于(1.5巴)vs.(0.1巴)来说的比率d50所确定的稳定性为≥5%,更优选≥7%,甚至更优选≥10%和最优选≥12%,例如12-90%或12-80%。
额外地,该粒料具有粒子内侵入式比孔容为0.15-2.75cm3/g,优选0.30-2.50cm3/g,最优选0.40-2.00cm3/g,由汞侵入孔隙率测定法测量结果计算。
该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子优选具有BET比表面积为1m2/g-200m2/g,优选2m2/g-150m2/g,更优选20m2/g-140m2/g,最优选40m2/g-70m2/g,根据ISO 9277:2010使用氮气和BET法测量。
进一步优选地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过使用激光衍射测量。
鉴于以上所述,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和/或
a)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
例如,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
优选地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定。
额外地或替代地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
因此,该粒料优选包含含镁离子材料的粒子,该含镁离子材料的粒子具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和/或
a)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和/或
b)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
例如,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
在一种实施方案中,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
a)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,或
b)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
优选地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量。
额外地或替代地,该粒料优选包含含镁离子材料的粒子,该含镁离子材料的粒子具有粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
例如,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和/或
c)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
在一种实施方案中,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
a)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和/或
b)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
例如,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,或
c)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
优选地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和
c)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
在一种优选实施方案中,该粒料因而包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
优选地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
更优选地,该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和
a)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定,和
b)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和
c)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
在一种实施方案中,该粒料包含至少一种崩解剂或任何可起到崩解剂作用的化合物。例如,该至少一种崩解剂选自交联羧甲基纤维素钠、改性纤维素胶、不溶性交联聚乙烯吡咯烷酮、淀粉、改性淀粉、淀粉羟乙酸盐如淀粉羟乙酸钠、微晶纤维素、预糊化淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、N-乙烯基-2-吡咯烷酮的均聚物、烷基纤维素酯、羟烷基纤维素酯、羧基烷基纤维素酯、藻酸、微晶纤维素及其多晶型、离子交换树脂、树胶、甲壳素、壳聚糖、粘土、结冷胶、交联泼拉克林共聚物、琼脂、明胶、糊精、丙烯酸聚合物、羧甲基纤维素钠/钙、邻苯二甲酸羟丙基甲基纤维素、虫胶、泡腾混合物如碳酸氢盐组合一种或多种酸如柠檬酸或酒石酸、或其混合物。
如果存在,该粒料包含该至少一种崩解剂(或任何可起到崩解剂作用的化合物),其量基于该粒料的总干重计为0.25-35%重量,优选0.5-15%重量,更优选0.5-10%重量,甚至更优选0.7-10%重量,最优选0.8-10重量。在一种实施方案中,该粒料包含该至少一种崩解剂(或任何可起到崩解剂作用的化合物),其量基于该粒料的总干重计为0.25-35%重量,优选0.5-15%重量,更优选0.5-10%重量,甚至更优选1.0-10%重量,最优选1.5-10%重量的。特别优选地,该粒料包含该至少一种崩解剂(或任何可起到崩解剂作用的化合物),其量基于该粒料的总干重计为0.8-8%重量,优选0.8-6%重量,更优选0.8-5%重量,最优选0.8-4%重量。
应理解,该粒料优选通过本文定义的方法获得。
因此,该粒料优选通过包括以下步骤的方法获得:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,以及
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料。
如果该粒料包含至少一种崩解剂(或任何可起到崩解剂作用的化合物),则该粒料优选通过包括以下步骤的方法获得:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料,以及
d)在步骤b)之前和/或期间和/或之后将至少一种崩解剂(或任何可起到崩解剂作用的化合物)添加到水性悬浮液中。
在一种优选实施方案中,该粒料通过包括以下步骤的方法获得:
a)提供包含含镁离子材料的水性悬浮液;
b)通过研磨均化步骤a)的包含含镁离子材料的水性悬浮液,以及
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料。
如果该粒料包含至少一种崩解剂(或任何可起到崩解剂作用的化合物),则该粒料优选通过包括以下步骤的方法获得:
a)提供包含含镁离子材料的水性悬浮液;
b)通过研磨均化步骤a)的包含含镁离子材料的水性悬浮液,
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料,以及
d)在步骤b)之前和/或期间和/或之后将至少一种崩解剂(或任何可起到崩解剂作用的化合物)添加到水性悬浮液中。
额外地或替代地,该粒料经受使用至少一种活性成分和/或其非活性前体的处理,使得该至少一种活性成分和/或其非活性前体基本上仅存在于该粒料的外表面上。
在本发明的含义中,术语“活性成分”是指在有机体中具有特定效果且在人类、动物、微生物和/或植物中引起特定反应的物质。
优选地,以液体形式提供该至少一种活性成分和/或其非活性前体。
在本发明的含义中,术语“液体”是指包含该至少一种活性成分和/或其非活性前体或由该至少一种活性成分和/或其非活性前体组成的非气态流体组合物,其在使用的压力条件和温度下(即在粒料与该至少一种活性成分和/或其非活性前体混合的压力和温度下)是易于流动的。
因此应理解,该至少一种活性成分和/或其非活性前体可在5-200℃、优选10-120℃且最优选10-100℃的温度范围内为液体。例如,该至少一种活性成分和/或其非活性前体可在环境压力条件下(即在大气压下)在5-200℃、优选10-120℃且最优选10-100℃的温度范围内为液体。另外可选地,该至少一种活性成分和/或其非活性前体可在减压条件下(例如在100-700毫巴的压力下)在5-200℃、优选10-120℃且最优选10-100℃的温度范围内为液体。
在一种实施方案中,该至少一种活性成分和/或其非活性前体在环境温度和压力条件下,例如在室温下如约5-35℃、优选10-30℃且最优选15-25℃下并且在大气压下为液体。
另外可选地,该至少一种活性成分和/或其非活性前体在使用温度下,例如在约35-200℃、优选45-120℃且最优选55-100℃下,并且在环境压力条件下即在大气压下,或在减压条件下如在100-700毫巴的压力下熔融。
另外可选地,使该至少一种活性成分和/或其非活性前体溶解在溶剂中。也就是说,该至少一种活性成分和/或其非活性前体与溶剂形成一种体系,在该体系中在溶剂中没有观察到离散的固体粒子,因此形成“溶液”。
在本发明的一种实施方案中,该溶剂选自水、甲醇、乙醇、正丁醇、异丙醇、正丙醇、丙酮、二甲基亚砜、二甲基甲酰胺、四氢呋喃、植物油及其衍生物、动物油及其衍生物、熔融脂肪和蜡、及其混合物。优选地,该溶剂为水、乙醇和/或丙酮。更优选地,该溶剂为水。
例如,该至少一种活性成分和/或其非活性前体可为手性化合物。因而,该至少一种活性成分和/或其非活性前体涵盖(R)-对映异构体、(S)-对映异构体及其混合物,例如外消旋混合物。
额外地或另外可选地,该至少一种活性成分和/或其非活性前体可为异构化合物。因而,该至少一种活性成分和/或其非活性前体涵盖(Z)-异构体、(E)-异构体及其混合物。例如,如果指出该活性成分为肉桂醛,则该肉桂醛可以以(Z)-肉桂醛和/或(E)-肉桂醛的形式存在。
例如,该至少一种活性成分和/或其非活性前体选自日用化妆香精,食用香精,草本提取物和油,水果提取物和油,营养剂,痕量矿物,防护剂,食品,化妆品,阻燃剂,酶,大分子,杀虫剂,肥料,防腐剂,抗氧化剂,反应性化学品,合成来源、半合成来源、天然来源的药物和/或营养品和/或兽医活性剂或者其药物和/或营养品和/或兽医非活性前体,及其混合物。
日用化妆香精优选为具有至少约100g/mol分子量的醇、醛和/或酮,且其单独或与其他日用化妆香精组合用于散发气味、芳香味、香精味或香味。例如,该日用化妆香精可选自2,4-二甲基-3-环己烯-1-甲醇(花香醇(floralol))、2,4-二甲基环己烷甲醇(二氢花香醇)、5,6-二甲基-1-甲基乙烯基双环[2.2.1]庚-5-烯-2-甲醇(亚波醇(arbozol))、α,α,-4-三甲基-3-环己烯-1-甲醇(α-松油醇)、2,4,6-三甲基-3-环己烯-1-甲醇(异环香叶醇)、4-(1-甲基乙基)环己烷甲醇(五月铃兰醇(mayol))、α-3,3-三甲基-2-降冰片烷甲醇、1,1-二甲基-1-(4-甲基环己-3-烯基)甲醇、2-苯乙醇、2-环己基乙醇、2-(邻甲基苯基)-乙醇、2-(间甲基苯基)乙醇、2-(对甲基苯基)乙醇、6,6-二甲基双环-[3.1.1]庚-2-烯-2-乙醇(诺卜醇(nopol))、2-(4-甲基苯氧基)-乙醇、3,3-二甲基-Δ2-β-降冰片烷乙醇(派奇明托(patchomint))、2-甲基-2-环己基乙醇、1-(4-异丙基环己基)-乙醇、1-苯乙醇、1,1-二甲基-2-苯乙醇、1,1-二甲基-2-(4-甲基-苯基)乙醇、1-苯基丙醇、3-苯基丙醇、2-苯基丙醇(向水性醇)、2-(环十二烷基)丙-1-醇(羟基龙涎呋喃(Hydroxy-ambran))、2,2-二甲基-3-(3-甲基苯基)-丙-1-醇(美研醇(Majantol))、2-甲基-3-苯基丙醇、3-苯基-2-丙烯-1-醇(肉桂醇)、2-甲基-3-苯基-2-丙烯-1-醇(甲基肉桂醇)、α-正戊基-3-苯基-2-丙烯-1-醇(α-戊基-肉桂醇)、乙基-3-羟基-3-苯基丙酸酯、2-(4-甲基苯基)-2-丙醇、3-(4-甲基环己-3-烯)丁醇、2-甲基-4-(2,2,3-三甲基-3-环戊烯-1-基)丁醇、2-乙基-4-(2,2,3-三甲基-环戊-3-烯基)-2-丁烯-1-醇、3-甲基-2-丁烯-1-醇(异戊烯醇)、2-甲基-4-(2,2,3-三甲基-3-环戊烯-1-基)-2-丁烯-1-醇、3-羟基丁酸乙酯、4-苯基-3-丁烯-2-醇、2-甲基-4-苯基丁-2-醇、4-(4-羟基苯基)丁-2-酮、4-(4-羟基-3-甲氧基苯基)-丁-2-酮、3-甲基-戊醇、3-甲基-3-戊烯-1-醇、1-(2-丙烯基)环戊-1-醇(鸢醇(plinol))、2-甲基-4-苯基戊醇(圆柚芳晶(Pamplefleur))、3-甲基-5-苯基戊醇(吩醇(Phenoxanol))、2-甲基-5-苯基戊醇、2-甲基-5-(2,3-二甲基三环[2.2.1.0.sup.(2,6)]庚-3-基)-2-戊烯-1-醇(檀香醇(santalol))、4-甲基-1-苯基-2-戊醇、5-(2,2,3-三甲基-3-环戊烯基)-3-甲基戊-2-醇(人造檀香(sandalore))、(1-甲基-双环[2.1.1]庚烯-2-基)-2-甲基戊-1-烯-3-醇、3-甲基-1-苯基戊-3-醇、1,2-二甲基-3-(1-甲基乙烯基)环戊-1-醇、2-异丙基-5-甲基-2-己烯醇、顺式-3-己烯-1-醇、反式-2-己烯-1-醇、2-异丙烯基-4-甲基-4-己烯-1-醇(熏衣草醇(Lavandulol))、2-乙基-2-异戊烯基-3-己烯醇、1-羟甲基-4-异丙烯基-1-环己烯(二氢对异丙苄基醇)、1-甲基-4-异丙烯基环己-6-烯-2-醇(香芹烯醇(carvenol))、6-甲基-3-异丙烯基环己-1-醇(二氢香芹烯醇)、1-甲基-4-异丙烯基环己-3-醇、4-异丙基-1-甲基环己-3-醇、4-叔丁基环己醇、2-叔丁基环己醇、2-叔丁基-4-甲基环己醇(香根醇(rootanol))、4-异丙基-环己醇、4-甲基-1-(1-甲基乙基)-3-环己烯-1-醇、2-(5,6,6-三甲基-2-降冰片基)环己醇、异冰片基环己醇、3,3,5-三甲基环己醇、1-甲基-4-异丙基环己-3-醇、1-甲基-4-异丙基环己烷-8-醇(二氢松油醇)、1,2-二甲基-3-(1-甲基乙基)环己-1-醇、庚醇、2,4-二甲基庚-1-醇、6-庚基-5-庚烯-2-醇(异沉香醇)、2,4-二甲基-2,6-庚烷二烯醇、6,6-二甲基-2-氧甲基-双环[3.1.1]庚-2-烯(桃金娘烯醇(myrtenol))、4-甲基-2,4-庚二烯-1-醇、3,4,5,6,6-五甲基-2-庚醇、3,6-二甲基-3-乙烯基-5-庚烯-2-醇、6,6-二甲基-3-羟基-2-亚甲基双环[3.1.1]庚烷、1,7,7-三甲基双环[2.2.1]庚-2-醇、2,6-二甲基庚-2-醇(二米吐尔(dimetol))、2,6,6-三甲基双环[1.3.3]庚-2-醇、辛醇、2-辛烯醇、2-甲基辛-2-醇、2-甲基-6-亚甲基-7-辛烯-2-醇(香叶烯醇(myrcenol))、7-甲基辛-1-醇、3,7-二甲基-6-辛烯醇、3,7-二甲基-7-辛烯醇、3,7-二甲基-6-辛烯-1-醇(香茅醇)、3,7-二甲基-2,6-辛二烯-1-醇(香叶醇)、3,7-二甲基-2,6-辛二烯-1-醇(橙花醇)、3,7-二甲基-7-甲氧基辛-2-醇(沙针醇(osyrol))、3,7-二甲基-1,6-辛二烯-3-醇(沉香醇)、3,7-二甲基辛-1-醇(香叶醇(pelargol))、3,7-二甲基辛-3-醇(四氢芳樟醇)、2,4-辛二烯-1-醇、3,7-二甲基-6-辛烯-3-醇(二氢沉香醇)、2,6-二甲基-7-辛烯-2-醇(二氢月桂烯醇)、2,6-二甲基-5,7-辛二烯-2-醇、4,7-二甲基-4-乙烯基-6-辛烯-3-醇、3-甲基辛-3-醇、2,6-二甲基辛-2-醇、2,6-二甲基辛-3-醇、3,6-二甲基辛-3-醇、2,6-二甲基-7-辛烯-2-醇、2,6-二甲基-3,5-辛二烯-2-醇(蘑菇醇(muguol))、3-甲基-1-辛烯-3-醇、7-羟基-3,7-二甲基辛醛、3-壬醇、2,6-壬二烯-1-醇、顺式-6-壬烯-1-醇、6,8-二甲基壬-2-醇、3-(羟甲基)-2-壬酮、2-壬烯-1-醇、2,4-壬二烯-1-醇、3,7-二甲基-1,6-壬二烯-3-醇、癸醇、9-癸烯醇、2-苄基-M-二氧杂-5-醇、2-癸烯-1-醇、2,4-癸二烯-1-醇、4-甲基-3-癸烯-5-醇、3,7,9-三甲基-1,6-癸二烯-3-醇(异丁基沉香醇)、十一烷醇、2-十一碳烯-1-醇、10-十一碳烯-1-醇、2-十二碳烯-1-醇、2,4-十二碳二烯-1-醇、2,7,11-三甲基-2,6,10-十二碳三烯-1-醇(法呢醇(farnesol))、3,7,11-三甲基-1,6,10,-十二碳三烯-3-醇(橙花叔醇(nerolidol))、3,7,11,15-四甲基十六碳-2-烯-1-醇(植醇(phytol))、3,7,11,15-四甲基十六碳-1-烯-3-醇(异植醇(isophytol))、苯甲醇、对甲氧基苯甲醇(茴香基醇(anisyl))、对伞花(cymen)-7-醇(对异丙苄基醇)、4-甲基苯甲醇、3,4-亚甲二氧基苯甲醇、水杨酸甲酯、水杨酸苄酯、顺式水杨酸-3-己烯酯、水杨酸正戊酯、2-苯乙基水杨酸酯、水杨酸正己酯、2-甲基-5-异丙基苯酚、4-乙基-2-甲氧基苯酚、4-烯丙基-2-甲氧基苯酚(丁香酚)、2-甲氧基-4-(1-丙烯基)苯酚(异丁香酚)、4-烯丙基-2,6-二甲氧基-苯酚、4-叔丁基苯酚、2-乙氧基-4-甲基苯酚、2-甲基-4-乙烯基苯酚、2-异丙基-5-甲基苯酚(麝香草酚)、邻羟基苯甲酸异戊酯、2-羟基-苯甲酸乙酯、2,4-二羟基-3,6-二甲基苯甲酸甲酯、3-羟基-5-甲氧基-1-甲苯、2-叔丁基-4-甲基-1-羟基苯、1-乙氧基-2-羟基-4-丙烯基苯、4-羟基甲苯、4-羟基-3-甲氧基苯甲醛、2-乙氧基-4-羟基苯甲醛、十氢-2-萘酚、2,5,5-三甲基-八氢-2-萘酚、1,3,3-三甲基-2-降冰片烷醇(葑醇(fenchol))、3a,4,5,6,7,7a-六氢-2,4-二甲基-4,7-亚甲基-1H-茚-5-醇、3a,4,5,6,7,7a-六氢-3,4-二甲基-4,7-亚甲基-1H-茚-5-醇、2-甲基-2-乙烯基-5-(1-羟基-1-甲基乙基)四氢呋喃、β-石竹烯醇、香草醛、乙基香草醛、肉桂醛、苯甲醛、苯乙醛、庚醛、辛醛、癸醛、十一烷醛、十一烯醛、十二烷醛、十三烷醛、甲基壬醛、二癸醛、茴香醛、香茅醛、香茅基氧基醛、仙客来醛、α-己基肉桂醛、羟基香茅醛、α-甲基肉桂醛、甲基壬基乙醛、丙基苯基醛、柠檬醛、紫苏醛、甲苯醛、甲苯乙醛、对异丙基苯甲醛、水杨醛、α-戊基肉桂醛和胡椒醛及其混合物。
也可使用各种精油、草本提取物和/或水果提取物,优选具有各种药用或者膳食补充性能的那些。精油、草本提取物和/或水果提取物通常是可以药用或用于调味的提取物或芳香植物、植物部分、水果或水果部分。适合的草本提取物和/或水果提取物可单独或在各种混合物中使用。常用精油、草本提取物和/或水果提取物包括紫锥花(Echinacea)、白毛茛(Goldenseal)、金盏草(Calendula)、迷迭香(Rosemary)、百里香(Thyme)、卡瓦椒(KavaKava)、芦荟(Aloe)、血根草(Blood Root)、葡萄柚籽提取物(Grapefruit Seed Extract)、黑升麻(Black Cohosh)、人参(Ginseng)、瓜拉那(Guarana)、蔓越橘(Cranberry)、银杏叶(Ginko Biloba)、圣约翰草(St.John's Wort)、月见草油(Evening Primrose Oil)、育亨宾树皮(Yohimbe Bark)、绿茶(Green Tea)、麻黄(Ma Huang)、玛咖(Maca)、覆盆子(Bilberry)、叶黄素(Lutein)、姜(Ginger)、含有丁香酚的油及其组合。
可使用各种营养剂,几乎包括任何维生素、矿物和/或植物化学成分。例如,可使用维生素A、维生素B1、维生素B6、维生素B12、维生素B2、维生素B6、维生素D、维生素E(即生育酚)、维生素K、硫胺素、核黄素、生物素、叶酸、烟酸、泛酸、Q10、α硫辛酸、二氢硫辛酸、姜黄素、叶黄素、β-隐黄质、番茄红素、叶黄素、玉米黄素、虾青素、β-胡萝卜素、胡萝卜素、混合类胡萝卜素、多酚、类黄酮、钠、钾、钙、镁、硫、氯、胆碱;和/或植物化学成分,例如类胡萝卜素、叶绿素、叶绿酸、纤维、类黄酮、花青素、矢车菊色素(cyaniding)、花翠素、锦葵色素、天竺葵色素、芍药色素、矮牵牛花素、黄烷醇、儿茶素、表儿茶素、表没食子儿茶素、表没食子儿茶素没食子酸酯、茶黄素、茶红素、原花青素、黄酮醇、槲皮素、堪非醇、杨梅素、异鼠李素、黄碱醇橙皮素(flavononeshesperetin)、柚皮素、圣草酚、桔皮素、黄酮类、芹黄素、木犀草素、木脂素、植物雌激素、白藜芦醇、异黄酮、大豆黄素、染料木黄酮、黄豆黄素、大豆异黄酮及其组合。可用作活性成分的营养剂的实例阐述于美国专利申请公开号20030157213A1、20030206993和20030099741A1中,出于所有目的,通过引用将其全文并入本文中。
在一种实施方案中,可使用痕量矿物,例如锰、锌、铜、氟、钼、碘、钴、铬、硒、磷及其组合。
酶可包括但不限于辅酶Q10、胃蛋白酶、植酸酶、胰蛋白酶、脂肪酶、蛋白酶、纤维素酶、乳糖酶及其组合。
杀虫剂(pesticides)优选为本领域技术人员已知的任何已知的除草剂、杀昆虫剂(insecticide)、昆虫生长调节剂、杀线虫剂、杀白蚁剂、杀软体动物剂、杀鱼剂、杀鸟剂、杀鼠剂、食肉动物毒杀剂(predacide)、杀菌剂、驱虫剂、动物趋避剂、抗微生物剂、杀真菌剂、消毒剂(disinfectant)(抗微生物剂)和消毒杀菌剂(sanitizer)。
应注意,防腐剂可为本领域技术人员已知的任何此类化合物。例如,防腐剂可包括但不限于苯氧基乙醇,乙基己基甘油,对羟基苯甲酸酯如对羟基苯甲酸甲酯,对羟基苯甲酸乙酯,对羟基苯甲酸丙酯,对羟基苯甲酸丁酯及其混合物,苯扎氯铵,氯丁醇,苯甲醇,氯化十六烷基吡啶酒石酸,乳酸,苹果酸,乙酸,苯甲酸,苯甲酸钠,山梨酸,山梨酸钾及其混合物。
抗氧化剂优选选自丁基羟基茴香醚(BHA),丁基羟基甲苯(BHT),没食子酸酯,类胡萝卜素,多酚如白藜芦醇,类黄酮及其混合物,多酚衍生物,生育酚及其盐,β胡萝卜素,泛醌(ubichinon),生育三烯酚,二氢槲皮素,天然来源的抗氧化剂及其混合物。如果抗氧化剂为天然来源的,则该抗氧化剂可为例如针叶树提取物,海岸松树皮提取物如来自瑞士Horphag的和/或余甘子果提取物如来从德国Sabinsa公司的/>
该药物活性剂或其药物非活性前体优选选自合成来源、半合成来源、天然来源及其组合的药物活性剂或药物非活性前体。
因而,药物活性剂涉及合成来源、半合成来源、天然来源及其组合的药物活性剂。另外,该药物活性剂的药物非活性前体涉及合成来源、半合成来源、天然来源及其组合的药物非活性前体并且将在随后阶段中被活化成相应的药物活性剂。
这种药物非活性前体的活化是本领域技术人员已知的并且常见地用在例如胃和/或胃肠途径中的活化,例如酸性活化或胰蛋白酶或糜蛋白酶裂解。
在本领域技术人员的理解范围内,所提及的活化方法仅具有说明性特性,且不旨在具有限制性特性。
应注意,该药物活性剂或其药物非活性前体可为本领域技术人员已知的任何此类化合物。
当施用于人和/或动物时,药物活性剂因而包括提供预防和/或治疗性能的任何化合物。实例包括但不限于药物活性剂、治疗活性剂、兽用活性剂、营养物和生长调节剂。
该药物活性剂或其药物非活性前体可为抗炎剂。这种试剂可包括但不限于非类固醇抗炎剂或NSAID,例如丙酸衍生物;乙酸衍生物;芬那酸衍生物;联苯羧酸衍生物;和昔康(oxicams)。所有这些NSAID被充分描述于Sunshine等人的美国专利第4,985,459号中,关于这些NSAID的描述,其全文通过引用并入本文中。可用的NSAID的实例包括乙酰水杨酸、布洛芬(ibuprofen)、萘普生(naproxen)、苯恶洛芬(benoxaprofen)、氟比洛芬(flurbiprofen)、非诺洛芬(fenoprofen)、芬布芬(fenbufen)、酮洛芬(ketoprofen)、吲哚洛芬(indoprofen)、吡洛芬(pirprofen)、卡洛芬(carprofen)、奥沙普嗪(oxaprozin)、普拉洛芬(pranoprofen)、微洛芬(microprofen)、硫恶洛芬(tioxaprofen)、舒洛芬(suprofen)、阿明洛芬(alminoprofen)、噻洛芬酸(tiaprofenic acid)、氟洛芬(fluprofen)、布氯酸(bucloxic acid)及其混合物。
同样可用的是类固醇抗炎药如氢化可的松等,以及COX-2抑制剂如美洛昔康(meloxicam)、塞来昔布(celecoxib)、罗非考昔(rofecoxib)、伐地考昔(valdecoxib)、艾托考昔(etoricoxib)或其混合物。可使用任何上述抗炎剂的混合物。
可用作药物活性剂或其药物非活性前体的其他材料包括常见已知的口腔和咽喉产品。这些产品包括但不限于上呼吸道试剂如苯肾上腺素、苯海拉明、右美沙芬(dextromethorphan)、溴己新和氯苯吡胺(chlorpheniramine);胃肠试剂如法莫替丁(famotidine)、洛哌丁胺(loperamide)和聚二甲基硅油;抗真菌剂如硝酸咪康唑(miconazole nitrate);抗生素和镇痛剂如酮洛芬和氟比洛芬(fluribuprofen)。
该药物活性剂或其药物非活性前体也可选自焦亚硫酸钠、丁基羟基甲苯、丁基化羟基苯甲醚。
该药物活性剂或其药物非活性前体也可选自麻黄碱(ephedrine)、镁加铝(magaldrate)、假麻黄碱(pseudoephedrine)、西地那非(sildenafil)、利多卡因(xylocaine)、苯扎氯铵(benzalconium chloride)、咖啡因(caffeine)、去养肾上腺素(phenylephrine)、安非拉酮(amfepramone)、奥利司他(orlistat)、西布曲明(sibutramine)、对乙酰氨基酚(acetaminophen)、阿司匹林(aspirin)、格列酮(glitazones)、二甲双胍(metformin)、氯丙嗪(chlorpromazine)、乘晕宁(dimenhydrinat)、多潘立酮(domperidone)、美克洛嗪(meclozine)、甲氧氯普胺(metoclopramide)、奥丹西隆(odansetron)、泼尼松龙(prednisolone)、普鲁米近(promethazine)、阿伐斯汀(acrivastine)、西替利嗪(cetirizine)、桂利嗪(cinnarizine)、氯马斯汀(clemastine)、赛克利嗪(cyclizine)、地氯雷他定(desloratadine)、右氯苯那敏(dexchlorpheniramine)、茶苯海明(dimenhydrinate)、依巴司汀(ebastine)、非索非那定(fexofenadine)、布洛芬(ibuprofen)、左沃普洛辛(levolevoproricin)、氯雷他定(loratadine)、美克洛嗪(meclozine)、咪唑斯汀(mizolastine)、普鲁米近(promethazine)、咪康唑(miconazole)、二乙酸氯己定(chlorhexidine diacetate)、氟化物、十肽KSL(decapeptide KSL)、氟化铝、氨基螯合钙(aminochelated calcium)、氟化铵、氟硅酸铵、单氟磷酸铵、氟化钙、葡萄糖酸钙、甘油磷酸钙、乳酸钙、单氟磷酸钙、碳酸钙、尿素、氯化十六烷基吡啶氯己定、二葡萄糖酸氯己定(chlorhexidine digluconate)、氯化氯己定(chlorhexidine chloride)、氯己定二乙酸酯(chlorhexidine diacetate)、CPP酪蛋白磷酸肽(CPP caseine phospho peptide)、赫克特丁(hexetedine)、十八碳烯基氟化铵(octadecentyl ammonium fluoride)、氟硅酸钾、氯化钾、单氟磷酸钾、碳酸氢钠、碳酸钠、氟化钠、氟硅酸钠、单氟磷酸钠、三聚磷酸钠、氟化亚锡、硬脂酰三羟乙基丙二胺二氢氟化物、氯化锶、焦磷酸四钾、焦磷酸四钠、正磷酸三钾、正磷酸三钠、藻酸、氢氧化铝、碳酸氢钠、西地那非(sildenafil)、他达拉非(tadalafil)、伐地那非(vardenafil)、育亨宾(yohimbine)、西咪替丁(cimetidine)、尼沙替丁(nizatidine)、雷尼替丁(ranitidine)、乙酰水杨酸、氯吡格雷(clopidogrel)、乙酰半胱氨酸、溴己新(bromhexine)、可待因(codeine)、右美沙芬(dextromethorphan)、苯海拉明(diphenhydramine)、诺斯卡品(noscapine)、苯丙醇胺(phenylpropanolamine)、维生素D、辛伐他汀(simvastatin)、吡沙可啶(bisacodyl)、乳糖醇(lactitol)、乳果糖(lactulose)、氧化镁、匹克硫酸钠、番泻叶苷(senna glycosides)、苯佐卡因(benzocaine)、利多卡因(lidocaine)、四卡因(tetracaine)、阿莫曲坦(almotriptan)、依来曲坦(eletriptan)、那拉曲坦(naratriptan)、利扎曲坦(rizatriptan)、舒马曲坦(sumatriptan)、佐米曲坦(zolmitriptan)、钙、铬、铜、碘、镁、锰、钼、磷、硒、锌、氯胺、氢过氧化物、甲硝唑、曲安奈德(triamcinolonacetonide)、苯索氯铵(benzethonium chl.)、十六基吡啶氯(cetylpyrid.chl.)、氯己定、氟化物、利多卡因、双性霉素(amphotericin)、咪康唑(miconazole)、制霉菌素(nystatin)、鱼油、银杏(ginkgo biloba)、人参、姜、紫松果菊(purpleconeflower)、锯棕榈(saw palmetto)、西替利嗪(cetirizine)、左旋西替利嗪(levocetirizine)、氯雷他定(loratadine)、双氯芬酸(diclofenac)、氟比洛芬(flurbiprofen)、阿伐斯丁假麻黄碱(acrivastine pseudoephedrine)、氯雷他定假麻黄碱(loratadine pseudoephedrine)、葡糖胺、透明质酸、十肽KSL-W、十肽KSL、白藜芦醇(resveratrol)、迷索前列醇(misoprostol)、安非他酮(bupropion)、盐酸恩丹西酮(ondansetron HCl)、埃索美拉唑(esomeprazole)、兰索拉唑(lansoprazole)、奥美拉唑(omeprazole)、泮托拉唑(pantoprazole)、雷贝拉唑(rabeprazole)、细菌等、洛哌丁胺(loperamide)、聚二甲基础硅油(simethicone)、乙酰水杨酸等、硫糖铝(sucralfate)、克霉唑(clotrimazole)、氟康唑(fluconazole)、伊曲康唑(itraconazole)、酮康唑(ketoconazole)、特比萘芬(terbinafine)、别嘌呤醇(allopurinol)、丙磺舒(probenecid)、阿托伐他汀(atorvastatin)、氟伐他汀(fluvastatin)、洛伐他汀(lovastatin)、烟酸(nicotinic acid)、普伐他汀(pravastatin)、罗素他汀(rosuvastatin)、辛伐他汀(simvastatin)、匹鲁卡品(pilocarpine)、萘普生(naproxen)、阿仑膦酸盐(alendronate)、依替膦酸盐(etidronate)、雷诺昔酚(raloxifene)、利塞膦酸盐(risedronate)、苯并二氮卓类(benzodiazepines)、戒酒硫(disulphiram)、纳曲酮(naltrexone)、丁丙诺啡(buprenorphine)、可待因(codeine)、右旋丙氧吩(dextropropoxyphene)、芬太尼(fentanyl)、氢吗啡酮(hydromorphone)、凯托米酮(ketobemidone)、酮洛芬(ketoprofen)、美沙酮(methadone)、吗啡(morphine)、萘普生(naproxen)、尼可吗啡(nicomorphine)、羟考酮(oxycodone)、哌替啶(pethidine)、曲马多(tramadol)、阿莫西林(amoxicillin)、氨苄青霉素(ampicillin)、阿奇霉素(azithromycin)、环丙沙星(ciprofloxacin)、克拉霉素(clarithromycin)、强力霉素(doxycyclin)、红霉素(erythromycin)、夫西地酸(fusidic acid)、赖甲环素(lymecycline)、甲硝唑(metronidazole)、莫西沙星(moxifloxacin)、氧氟沙星(ofloxacin)、土霉素(oxytetracycline)、苯氧基甲基青霉素(phenoxymethylpenicillin)、利福霉素(rifamycins)、罗红霉素(roxithromycin)、磺胺噻唑(sulphamethizole)、四环素(tetracycline)、甲氧苄啶(trimethoprim)、万古霉素(vancomycin)、阿卡波糖(acarbose)、格列本脲(glibenclamide)、格列齐特(gliclazide)、格列美脲(glimepiride)、格列吡嗪(glipizide)、胰岛素(insulin)、瑞格列奈(repaglinide)、甲苯磺丁脲(tolbutamide)、奥司他韦(oseltamivir)、阿昔洛韦(aciclovir)、泛昔洛韦(famciclovir)、喷昔洛韦(penciclovir)、缬更昔洛韦(valganciclovir)、氨氯地平(amlopidine)、地尔硫卓(diltiazem)、非洛地平(felodipine)、硝苯地平(nifedipine)、维拉帕米(verapamil)、非那雄胺(finasteride)、米诺地尔(minoxidil)、可卡因(cocaine)、丁丙诺啡(buphrenorphin)、氯压定(clonidine)、美沙酮(methadone)、纳曲酮(naltrexone)、钙拮抗剂(calciumantagonists)、氯压定(clonidine)、麦角胺(ergotamine)、β-阻断剂(β-blockers)、醋氯芬酸(aceclofenac)、塞内昔布(celecoxib)、右布洛芬(dexiprofen)、依托度酸(etodolac)、吲哚美辛(indometacin)、酮洛芬(ketoprofen)、酮咯酸(ketorolac)、氯诺昔康(lornoxicam)、美洛昔康(meloxicam)、萘丁美酮(nabumetone)、厄罗昔康(oiroxicam)、帕瑞考昔(parecoxib)、保泰松(phenylbutazone)、吡罗昔康(piroxicam)、噻洛芬酸(tiaprofenic acid)、托芬那酸(tolfenamic acid)、阿立哌唑(aripiprazole)、氯丙嗪(chlorpromazine)、氯丙硫葸(chlorprothixene)、氯氮平(clozapine)、氟哌噻吨(flupentixol)、氟非那嗪(fluphenazine)、氟哌啶醇(haloperidol)、碳酸锂、柠檬酸锂、美哌隆(melperone)、五氟利多(penfluridol)、哌氰嗪(periciazine)、奋乃静(perphenazine)、哌迷清(pimozide)、匹泮哌隆(pipamperone)、丙氯拉嗪(prochlorperazine)、利培酮(risperidone)、硫醚嗪(thioridizin)、氟康唑(fluconazole)、伊曲康唑(itraconazole)、酮康唑(ketoconazole)、伏立康唑(voriconazole)、鸦片(opium)、苯二氮卓(benzodiazepines)、氢新(hydroxine)、甲丙胺酯(meprobamate)、啡噻嗪(phenothiazine)、氨基乙酸铝(aluminiumaminoacetate)、艾美拉唑(esomeprazole)、法莫替丁(famotidine)、氧化镁、尼扎替丁(nizatide)、奥美拉唑(omeprazole)、泮托拉唑(pantoprazole)、氟康唑(fluconazole)、伊曲康唑(itraconazole)、酮康唑(ketoconazole)、甲硝唑(metronidazole)、苯丙胺(amphetamine)、阿替洛尔(atenolol)、富马酸比索洛尔(bisoprolol fumarate)、美托洛尔(metoprolol)、美托洛尔(metropolol)、吲哚洛尔(pindolol)、普萘洛尔(propranolol)、金诺芬(auranofin)和苄达酸(bendazac)。
可用的药物活性剂或其药物非活性前体的其他实例可包括选自以下治疗剂的活性成分:镇痛剂、麻醉剂、退热剂、抗过敏药、抗心律失常剂、食欲抑制剂、抗真菌剂、抗炎剂、支气管扩张剂、心血管药物、冠状动脉扩张剂、脑扩张剂、外周血管扩张剂、抗感染剂、精神药物、抗躁狂剂、兴奋剂、抗组胺药、轻泻剂、减充血剂、胃肠镇静剂、性功能障碍剂、消毒剂、抗腹泻剂、抗心绞痛剂、血管扩张剂、抗高血压剂、血管收缩剂、偏头痛治疗剂、抗生素、镇静剂、抗精神病剂、抗肿瘤药物、抗凝血剂、抗血栓剂、催眠剂、镇静剂、止吐剂、抗恶心剂、抗惊厥剂、神经肌肉剂、高血糖剂和低血糖剂、甲状腺剂和抗甲状腺剂、利尿剂、抗痉挛剂、子宫松弛剂、抗肥胖剂、厌食剂、解痉剂、合成代谢剂、促红细胞生成剂、抗哮喘剂、祛痰剂、咳嗽抑制剂、黏液溶解剂、抗尿毒症剂、牙科赋形剂、口气清新剂、抗酸剂、抗利尿剂、抗胀气剂、β阻断剂、牙齿增白剂、酶、辅酶、蛋白质、能量增强剂、纤维、益生菌、益生元、NSAID、止咳剂、碱充血剂、抗组胺药、祛痰剂、止泻剂、氢拮抗剂、质子泵抑制剂、通用非选择性CNS抑制剂、通用非选择性CNS兴奋剂、选择性CNS功能改良药物、抗帕金森病药、麻醉镇痛药、镇痛剂、精神药理学药和性功能障碍剂。
可用的药物活性剂或其药物非活性前体的实例也可包括:酪蛋白糖基巨肽(CGMP)、三氯生(Triclosan)、氯化十六烷基吡啶溴化度米芬(Domiphen bromide)、季铵盐、锌组分、血根碱、氟化物、阿来西定(Alexidine)、欧克尼定(Octonidine)、EDTA、阿司匹林、对乙酰氨基酚、布洛芬、酮洛芬、二氟尼柳(diflunisal)、非诺洛芬钙、萘普生、托美丁钠、吲哚美辛、苯佐那酯(Benzonatate)、乙二磺酸卡拉美芬(Caramiphen edisylate)、薄荷醇、氢溴酸右美沙芬、盐酸可可碱、盐酸氯苯达诺(Chlophendianol Hydrochloride)、盐酸假麻黄碱、苯肾上腺素(Phenylephrine)、苯丙醇胺、硫酸假麻黄碱、马来酸溴苯那敏(Brompheniramine maleate)、马来酸氯苯那敏(Chlorpheniramine maleate)、马来酸卡比沙明(Carbinoxamine maleate)、富马酸氯马斯汀(Clemastine fumarate)、马来酸地氯苯那敏(Dexchlorpheniramine maleate)、盐酸苯海拉明(Dephenhydraminehydrochloride)、盐酸二苯胺、马来酸哌吡庚啶(Azatadine maleate)、柠檬酸苯海拉明(Diphenhydramine citrate)、琥珀酸多西拉敏(Doxylamine succinate)、盐酸异丙嗪(Promethazine hydrochloride)、马来酸吡拉明(Pyrilamine maleate)、柠檬酸三苯胺(Tripellenamine citrate)、盐酸曲普利啶(Triprolidine hydrochloride)、阿昔伐他汀(Acrivastine)、氯雷他定(Loratadine)、溴苯那敏(Brompheniramine)、德溴非明(Dexbrompheniamine)、愈创甘油醚(Guaifenesin)、吐根(Ipecac)、碘化钾、水合萜品(Terpin hydrate)、洛哌丁胺(Loperamide)、法莫替丁(Famotidine)、雷尼替丁(Ranitidine)、奥美拉唑(Omeprazole)、兰索拉唑(Lansoprazole)、脂族醇、巴比妥酸盐(Barbiturate)、咖啡因(caffeine)、马钱子碱(strychnine)、木防己苦毒素(Picrotoxin)、戊四氮、苯基乙内酰脲、苯巴比妥(Phenobarbital)、普里米酮(Primidone)、卡马西平(Carbamazapine)、乙琥胺、甲琥胺、苯琥胺(Phensuximide)、三甲双酮(Trimethadione)、地西泮(Diazepam)、苯并二氮卓(Benzodiazepine)、苯乙酰脲、苯丁酰脲、乙酰唑胺、苏太明(Sulthiame)、溴化物、左旋多巴(Levodopa)、金刚胺(Amantadine)、吗啡碱(Morphine)、海洛因(Heroin)、氢吗啡酮(Hydromorphone)、美托酮(Metopon)、羟吗啡酮(Oxymorphone)、左吗喃(Levophanol)、可待因(Codeine)、氢可酮(Hydrocodone)、羟考酮(Xycodone)、纳洛芬(Nalorphine)、纳洛酮(Naloxone)、纳曲酮(Naltrexone)、水杨酸盐、苯基丁氮酮(Phenylbutazone)、吲哚美辛(Indomethacin)、非那西汀(Phenacetin)、氯丙嗪(Chlorpromazine)、左美丙嗪(Methotrimeprazine)、氟哌啶醇(Haloperidol)、氯氮平(Clozapine)、利血平(Reserpine)、丙咪嗪(Imipramine)、反苯环丙胺(Tranylcypromine)、苯乙肼(Phenelzine)、锂、柠檬酸西地那非(Sildenafil citrate)、他达拉非(Tadalafil)和伐地那非CL(Vardenafil CL)。例如,丁香酚可被用作麻醉剂。
可用的药物活性剂或其药物非活性前体的实例可包括选自以下的活性成分:ACE抑制剂、抗心绞痛药、抗心律失常剂、抗哮喘剂、抗胆固醇血剂、镇痛剂、麻醉剂、抗惊厥剂、抗抑郁剂、抗糖尿病剂、抗腹泻制剂、解毒剂、抗组胺药、抗高血压药、抗炎剂、抗脂质剂、抗躁剂、止恶心药、抗中风剂、抗甲状腺制剂、抗肿瘤药物、抗病毒剂、痤疮药物、生物碱、氨基酸制剂、止咳剂、抗尿毒症剂、抗病毒药物、合成代谢制剂、全身和非全身抗感染剂、抗肿瘤药、抗帕金森病剂、抗风湿病剂、食欲刺激剂、生物学反应调节剂、血液改良剂、骨骼代谢调节剂、心血管剂、中枢神经系统刺激剂、胆碱酯酶抑制剂、避孕药、碱充血剂、膳食补充剂、多巴胺受体促效剂、子宫内膜异位处理剂、酶、勃起功能障碍疗法(例如目前以ViagraTM出售的柠檬酸西地那非(sildenafil citrate)、生育剂、胃肠道药、顺势疗法治疗物、激素、高钙血症处理剂和低钙血症处理剂、免疫调节剂、免疫抑制剂、偏头痛制剂、动晕症治疗剂、肌肉松弛剂、肥胖管理剂、骨质疏松症制剂、催产剂、副交感神经阻断药、副交感神经药、前列腺素、精神治疗剂、呼吸道剂、镇静剂、戒烟助剂(例如溴麦角环肽)、交感神经剂、震颤制剂、泌尿道药、血管扩张剂、轻泻剂、抗酸剂、离子交换树脂、退烧药、食欲抑制剂、祛痰剂、抗焦虑剂、抗溃疡剂、抗炎物质、冠状动脉扩张剂、脑扩张剂、外周血管扩张剂、精神药物、兴奋剂、抗高血压药物、血管收缩剂、偏头痛治疗剂、抗生素、安神剂、抗精神病药、抗肿瘤药物、抗凝血剂、抗血栓药物、安眠药、止吐药、抗恶心药、抗惊厥剂、神经肌肉药、高血糖剂和低血糖剂、甲状腺和抗甲状腺制剂、利尿剂、抗痉挛药、子宫松弛剂、抗肥胖药物、促红血球生成药、抗哮喘剂、止咳剂、黏液溶解剂、DNA和遗传修饰药以及其组合。
预期可用的药物活性剂或其药物非活性前体的实例也可包括抗酸剂、H2-拮抗剂和镇痛剂。例如,可单独使用碳酸钙成分或与氢氧化镁和/或氢氧化铝组合来制备抗酸剂。此外,抗酸剂可与H2-拮抗剂组合使用。
镇痛剂包括鸦片制剂以及鸦片制剂衍生物,例如OxycontinTM、布洛芬、阿司匹林、对乙酰氨基酚及其可任选地包括咖啡因的组合。
其他可用的药物活性剂或其药物非活性前体可包括止泻剂,例如ImmodiumTMAD、抗组胺药、止咳剂、碱充血剂、维生素和口气清新剂。也预期在本文中使用的是抗焦虑剂,例如XanaxTM;抗精神病药,例如ClozarilTM和HaldolTM;非类固醇抗炎剂(NSAID),例如布洛芬、萘普生钠、VoltarenTM和LodineTM;抗组胺药,例如ClaritinTM、HismanalTM、RelafenTM和TavistTM;止吐药,例如KytrilTM和CesametTM;支气管扩张剂,例如BentolinTM、ProventilTM;抗抑郁药,例如ProzacTM、ZoloftTM和PaxilTM;抗偏头痛剂,例如ImigraTM;ACE抑制剂,例如VasotecTM、CapotenTM和ZestrilTM;抗阿尔茨海默病药,例如NicergolineTM;以及CaH拮抗剂,例如ProcardiaTM、AdalatTM和CalanTM。
预期用于本发明中的普遍的H2-拮抗剂包括西咪替丁、盐酸雷尼替丁、法莫替丁、尼沙替丁(nizatidine)、乙溴替丁(ebrotidine)、咪芬替丁(mifentidine)、罗沙替丁(roxatidine)、匹沙替丁(pisatidine)和乙酸罗沙替丁(aceroxatidine)。
活性抗酸成分可包括但不限于以下物质:氢氧化铝、氨基乙酸二羟基铝、氨基乙酸、磷酸铝、碳酸二羟铝钠、碳酸氢盐、铝酸铋、碳酸铋、碱式碳酸铋、碱式没食子酸铋、次硝酸铋、次水杨酸铋(bismuth subsilysilate)、磷酸钙、柠檬酸根离子(酸或盐)、氨基乙酸、水合硫酸镁铝、镁加铝、硅酸镁铝、碳酸镁、甘氨酸镁、氢氧化镁、氧化镁、三硅酸镁、乳固体、磷酸氢二或二氢铝钙、磷酸三钙、碳酸氢钾、酒石酸钠、碳酸氢钠、硅酸镁铝、酒石酸和盐。
在一些实施方案中,该药物活性剂或其药物非活性前体可选自镇痛剂/麻醉剂,例如薄荷醇、苯酚、己基间苯二酚、苯佐卡因、盐酸达克罗宁、苯甲醇、水杨醇及其组合。在一些实施方案中,该药物活性剂或其药物非活性前体可选自缓和剂,例如滑榆树皮(slipperyelm bark)、果胶、明胶及其组合。在一些实施方案中,该药物活性剂或其药物非活性前体可选自防腐败剂(antiseptic)成分,例如氯化十六烷基吡啶溴化杜米芬(domiphenbromide)、地喹氯铵(dequalinium chloride)、丁香酚及其组合。
在一些实施方案中,该药物活性剂或其药物非活性前体可选自止咳成分,例如盐酸氯苯达诺、可待因、磷酸可待因、硫酸可待因、右美沙芬、氢溴酸右美沙芬、柠檬酸苯海拉明和盐酸苯海拉明及其组合。
在一些实施方案中,该药物活性剂或其药物非活性前体可选自咽喉舒缓剂,例如蜂蜜、蜂胶、芦荟(aloe vera)、丙三醇、薄荷醇及其组合。在其他实施方案中,该药物活性剂或其药物非活性前体可选自咳嗽抑制剂。这种咳嗽抑制剂可分成两组:改变痰的质地或产量的那些,例如黏液溶解剂和祛痰药;以及抑制咳嗽反射的那些,例如可待因(麻醉性咳嗽抑制剂)、抗组胺、右美沙芬和异丙肾上腺素(非麻醉性咳嗽抑制剂)。
在其他实施方案中,该药物活性剂或其药物非活性前体可选自以下的止咳剂:可待因、右美沙芬、右羟吗喃、苯海拉明、氢可酮、诺斯卡品、羟考酮、喷托维林及其组合。在一些实施方案中,该药物活性剂或其药物非活性前体可选自抗组胺药,例如阿伐斯汀、阿扎他定、溴苯那敏、氯非尼拉敏、氯马斯汀、赛庚啶、右溴苯那敏、茶苯海明、苯海拉明、苯吡拉明、安泰乐、美克利嗪、苯茚胺、苯托沙敏、普鲁米近、比拉明、曲吡那明、曲普利定及其组合。在一些实施方案中,该药物活性剂或其药物非活性前体可选自非镇静抗组胺药,例如阿司咪唑、西替利嗪、依巴斯汀、非索非那定、氯雷他定、特非那定及其组合。
例如,该一种或多种活性成分选自日用化妆香精,食用香精,精油,杀虫剂,杀真菌剂,药物活性剂或其药物非活性前体如防腐败剂和/或麻醉剂,及其混合物。
如果该粒料包含至少一种活性成分和/或其非活性前体,则基于该粒料的总干重计,该至少一种活性成分和/或其非活性前体优选以0.5-80%重量、优选10.0-70%重量且最优选20-60%重量的量存在于该粒料中。
还要指出,与通过缺少均化步骤b)的方法生产的粒料相比,本发明的粒料具有改善的流动性、压实性以及机械稳定性。
除此之外,该粒料是即用型粒料,用在用于生产可分散剂型的进一步方法中。这样的剂型是包含这些粒料的片剂、迷你片剂、丸粒、胶囊、果冻豆或可咀嚼胶(口香糖)。
除此之外,该粒料和上述剂型可被用在营养产品、农业产品、兽医产品、化妆产品、家用产品、食物产品、包装产品或个人护理产品中,或者在药物产品中用作赋形剂。
应理解,该化妆产品优选为干化妆品和/或干皮肤护理组合物,更优选干化妆品组合物。例如,该干化妆品组合物是化妆品粉末,包括眼影、粉末化妆品、唇粉、扑面粉、体粉或红色敷面粉。根据另一种实施方案,该化妆产品是干皮肤护理组合物。例如,该干皮肤护理组合物可以是皮肤护理粉末,包括剃须粉、体粉、婴儿用爽身粉、足粉和祛臭粉。根据又一种实施方案,该干化妆品和/或干皮肤护理组合物是干化妆品和皮肤护理组合物。
该个人护理产品优选为口腔护理组合物。在一种实施方案中,口腔护理组合物是牙膏,牙胶,牙粉,粘固剂(cement),在口腔条或颊部粘合贴片上进行的组合物,(可咀嚼)牙片,可咀嚼锭剂或可咀嚼胶(口香糖),优选牙膏,牙粉,牙粉或(可咀嚼)牙片。
此外,该粒料和上述剂型可被用在空气处理和水处理中。
例如,如果该粒料和上述剂型被用在空气处理中,它们特别适合于吸收和/或去除空气中的污染物,例如NOx、SO2、HCl和/或HF物质。如果该粒料和上述剂型被用在水处理中,它们特别适合于吸收和/或去除水中的污染物,例如重金属。
例如,该粒料可以与表面活性剂组合使用。特别地,该表面活性剂可被装载到该粒料上。
在本发明的一种实施方案中,该表面活性剂可选自阴离子表面活性剂、阳离子表面活性剂,两性表面活性剂和非离子表面活性剂。
适用于本发明的阴离子表面活性剂可以是任何在水处理领域中已知的阴离子表面活性剂。例如,该阴离子表面活性剂选自烷烃磺酸盐、烯烃磺酸盐、脂肪酸酯磺酸盐如甲基或乙基酯磺酸盐、烷基芳基磺酸盐、烷基膦酸酯盐、烷基醚膦酸酯盐、牛磺酸盐、烷基醚羧酸盐、脂肪酸、C8-C22烷基硫酸盐、C8-C22烷基苯硫酸酯及其盐,C8-C22烷基烷氧基硫酸酯及其盐如十二烷基醚硫酸钠、C12-C22甲基酯磺酸酯及其盐、C12-C22烷基苯磺酸酯及其盐如十二烷基苯磺酸钠、C12-C22脂肪酸皂及其盐及其混合物。
适用于本发明的非离子表面活性剂可以是任何在水处理领域中已知的非离子表面活性剂。例如,该非离子表面活性剂选自烷基乙氧基化物如C8-C22烷基乙氧基化物、C6-C12烷基酚烷氧基化物、烷基多糖、烷基聚葡糖苷表面活性剂、葡糖酰胺、甲基酯烷氧基化物、烷氧基化的醇如烷氧基化的C12-C22醇、聚酰胺乳化剂、环氧乙烷/环氧丙烷嵌段共聚物、脂肪醇、脂肪醇烷氧基化物、任选改性的脂肪醇烷氧基化物、脂肪酸烷氧基化物如脂肪酸乙氧基化物、任选改性的脂肪酸烷氧基化物、乙氧基化或丙氧基化的脱水山梨糖醇酯、多羟基脂肪酸酰胺、鼠李糖脂、葡糖脂(glucoselipids)、脂肽及其混合物。
适用于本发明的阳离子表面活性剂可以是任何在水处理领域中已知的阳离子表面活性剂。例如,有用的阳离子表面活性剂可选自脂肪胺、季铵盐、酯季铵盐(esterquats)(即季铵化的脂肪酸表面活性剂)、及其混合物。
适用于本发明的两性表面活性剂可以是任何在水处理领域中已知的两性表面活性剂。例如,该两性表面活性剂可以选自仲胺或叔胺的脂族衍生物和/或杂环仲胺和叔胺的脂族衍生物,其中脂族基团可以是直链或支链的。
在本发明的一种优选实施方案中,该表面活性剂选自烷基乙氧基化物、季铵盐、环氧乙烷/环氧丙烷嵌段共聚物、脂肪酸及其盐、烷基芳基磺酸盐、脂肪醇、硬脂酸铝、非离子聚酰胺乳化剂及其混合物,并且最优选地,该表面活性剂选自C8-C22烷基乙氧基化物、C6-C12烷基酚烷氧基化物、妥尔油、脂油、其盐和衍生物、以及上述物质的混合物。
术语“非离子聚酰胺乳化剂”被理解为是指基于与聚胺交联的脂肪酸的非离子聚酰胺乳化剂。非离子聚酰胺乳化剂的合适实例是本领域技术人员已知的。
在一种示例性实施方案中,该表面活性剂选自脂肪酸及其盐。合适的脂肪酸包括饱和以及不饱和脂肪酸,即饱和以及不饱和羧酸,例如上文在表面处理剂的范围内所述的那些。脂肪酸的合适盐包括饱和以及不饱和脂肪酸的钙和镁盐。适合用作本发明中的表面活性剂的脂肪酸的说明性实例是亚油酸。
在另一示例性实施方案中,该表面活性剂选自妥尔油、脂油、其盐和衍生物。适用于本发明的妥尔油和脂油的盐包括妥尔油和脂油的钙盐和镁盐。妥尔油或脂油可任选地衍生化,例如通过氧化、通过衍生化为脂胺(例如通过与单胺、二胺或多胺反应)、通过乙氧基化或烷氧基化或通过上述衍生化方法中两种或更多种的组合来实现。适用于本发明的脂油衍生物的说明性实例是乙氧基化的脂胺,例如以商品名Aduxol可获自的那些,例如乙氧基化的脂油丙烯二胺Aduxol TPA-03D。
在任何前述实施方案中,术语“乙氧基化(的)”或“烷氧基化(的)”被理解为涉及通过分别添加(低聚)亚乙基氧基-(CH2-CH2-O-)n或亚烷基氧基-(Y-O-)n进行相应化合物的改性,其中Y=具有2-6个碳原子的亚烷基并且n=1-200,优选3-40。
应理解,本发明含义中的术语表面活性剂也可以包含两种或更多种表面活性剂的混合物。
迷你片剂或片剂在本领域中是众所周知的,且具有通常用于待制备产品的粒子尺寸。
例如,根据机械筛分测量,该迷你片剂或片剂具有0.1-20.0mm、优选0.2-15.0mm且更优选0.3-10.0mm的重量中值粒子尺寸d50。
鉴于以上所述,本发明的另一个方面涉及如本文所定义的粒料在营养产品、农业产品、兽医产品、化妆产品中、优选在干化妆品和/或干皮肤护理组合物中、在家用产品、食物产品、包装产品、个人护理产品中、优选在口腔护理组合物中、在空气处理和水处理中、或者在药物产品中作为赋形剂的用途。
以下实施例和测试将说明本发明,但并不旨在以任何方式限制本发明。
附图说明
图1显示了粒料PHM1的SEM结果。
图2显示了粒料PHM2的SEM结果。
图3显示了粒料PHM3的SEM结果。
图4显示了粒料PHM4的SEM结果。
图5显示了粒料PHM5的SEM结果。
具体实施方式
实施例
测量方法
下面将描述在实施例中使用的测量方法
粒子尺寸分布
使用Malvern Mastersizer 2000或3000激光衍射系统(Malvern InstrumentsPlc.,英国)在湿单元中评价体积确定的中值粒子尺寸d50(vol)和体积确定的顶切粒子尺寸d98(vol)以及体积粒子尺寸d90(vol)和d10(vol)。d50(vol)或者d98(vol)值表示的直径值使得以体积计分别为50%或者98%的粒子具有小于该值的直径。使用米氏(Mie)理论分析通过测量结果获得的原始数据,其中粒子折射率为1.57并且吸收系数为0.005。方法及仪器为本领域技术人员已知并且常见地用于确定填料和颜料的粒子尺寸分布。样品在无任何预先处理的情况下在干燥条件下测量。
通过在重力场中沉降行为分析的沉降方法测量重量确定的中值粒子尺寸d50(wt)。用美国Micromeritics Instrument公司的SedigraphTM 5120进行测量。方法及仪器是本领域技术人员已知的并且常见地用于确定填料和颜料的粒子尺寸分布。在0.1%重量的Na4P2O7的水溶液中进行测量。使用高速搅拌器及超声分散样品。
方法和仪器是本领域技术人员已知的并且常见地用于测定填料和颜料的颗粒尺寸。
如果在以下的实施例部分中没有另外指出,则使用Malvern Mastersizer 3000激光衍射系统(Malvern Instruments Plc.,英国)在湿单元中评价体积粒子尺寸。
比表面积(SSA)
本发明含义中的BET比表面积被定义为粒子的表面积除以粒子的质量。如本文所用,比表面积以m2/g为单位。
经由根据ISO 9277:2010的BET法,使用氮气,在通过在110℃(当使用崩解剂时)下或在250℃(如果样品不含崩解剂)下加热30分钟的周期调理样品之后测量比表面积。如果样品为水性悬浮液的形式,则在这种测量之前,样品在布氏漏斗中过滤、用去离子水冲洗并且在110℃下在烘箱中干燥至少12小时。
粒子内侵入式比孔容(以cm3/g计)
使用Micromeritics Autopore V 9620汞孔率计,使用汞侵入孔隙率测定法测量结果测量比孔容,所述汞孔率计具有最大施加汞压为414MPa(60 000psi),等效于0.004μm(~nm)的拉普拉斯喉径。在每个压力步骤使用的平衡时间是20秒。将样品材料密封在5cm3室的粉末透度计中用于分析。使用软件Pore-Comp(Gane,P.A.C.,Kettle,J.P.,Matthews,G.P.和Ridgway,C.J.,“Void Space Structure of Compressible Polymer Spheres andConsolidated Calcium Carbonate Paper-Coating Formulations”,Industrial andEngineering Chemistry Research,35(5),1996年,第1753-1764页),针对汞压缩、透度计膨胀和样品材料压缩来校正数据。
在累积侵入数据中见到的总孔体积可被分成两个区域,其中从214μm降至约1-4μm的侵入数据显示具有强烈贡献的任何附聚结构之间的样品的粗填充。在这些直径之下的是粒子自身的精细粒子间填充。如果它们也具有粒子内孔,则此区域显现双峰,并且通过获取由汞侵入比峰转折点更细(即比双峰拐点更细)的孔的比孔容,比粒子内孔体积被定义。这三个区域的总和给出了粉末的总全部孔体积,但强烈地取决于原始样品压实/在分布的粗孔末端处的粉末的沉降。
通过获取累积侵入曲线的第一导数,揭示了基于等效拉普拉斯直径的孔尺寸分布,其必然包括孔屏蔽。微分曲线清楚地显示了粗附聚孔结构区域、粒子间孔区域和粒子内孔区域(如果存在的话)。已知粒子内孔直径范围,则可以从总孔体积中减去剩余粒子间和附聚体间孔体积,以给出在每单位质量孔体积(比孔容)方面的单独的内部孔的希望的孔体积。当然,相同的减法原理也适用于分离任何感兴趣的其它孔尺寸区域。
堆密度
经由粉末漏斗,将100±0.5g的相应材料小心地填充至250mL量筒中且以最接近的1mL读取体积。根据下式计算松散堆密度:
松散堆密度[g/mL]=经称重的样品[g]/堆体积[mL]
并且以最接近的0.01g/mL记录结果。
Brookfield粘度
Brookfield粘度通过Brookfield(RVT型)粘度计在25℃±1℃、100rpm下,使用适当的转子在30秒后测量,单位为mPa·s。
悬浮材料的固体重量(%重量)
固体重量通过固体材料的重量除以水性悬浮液的总重量来确定。固体材料的重量通过称重通过蒸发浆料的水相并将获得的材料干燥至恒重而获得的固体材料来确定。
粒料稳定性
Malvern Mastersizer 3000(Malvern Instruments Plc.,英国)与Malvern AeroS干分散单元和干池组合用于通过激光衍射测定粒料在5-300μm的d50细度范围内的粒子尺寸分布。所使用的方法被描述在由Malvern Instruments Ltd提供的Mastersizer3000Basic Guide、Mastersizer 3000Manual和用于Aero Series Dry分散单元的Manual中。通过相应的筛将大约10ml的样品加载到Aero S中。干燥测量样品。结果以V.-%(体积%)表示。进料速率在0.1巴、0.5巴和1.5巴下进行以显示粒料稳定性。
0.1巴的进料速率被用来测定粒料的粒子尺寸分布。
扫描电镜(SEM)
通过以5ml的水稀释50-150μl的浆料样品来制备样品。浆料样品的量取决于固体含量、粒子尺寸平均值及粒子尺寸分布。使用0.8μm的膜滤器过滤稀释的样品。当滤液混浊时,使用更精细的过滤器。将双面导电胶带安装在SEM导体棒(stub)上。接着将此SEM导体棒轻轻压在过滤器上仍然湿的滤饼中。然后以8nm Au溅射SEM导体棒。FESEM(Zeiss SigmaVP)下的研究在5kV(Au)下进行。随后,通过使用Sigma VP场发射扫描电子显微镜(CarlZeiss AG,德国)和二次电子检测器(SE2)在高真空(<10-2Pa)下检查制备的样品。
机械筛分
机械筛分在配备有Easy Sieve Software的振动筛振动器RETSCH AS200中进行,筛根据ISO 3310,包含筛盘和天平(0.1g)。使用120g进行筛分。使测量的样品均匀,以最大限度地确保筛分的可再现性。将测量的样品材料放入上部测试筛中。筛分采用以下方法进行:筛分时间:3分钟/振幅:1.0/间隔:10秒。
吸油率
吸油率根据ISO 787/5进行测定。
2、使用的材料
沉淀(或合成)水菱镁矿(PHM-a)
PHM-a通过如下方式获得:将3600kg细研磨的苛性煅烧菱镁矿(MgO)经由进入反应器容器的顶部开口添加到40000升温度为55℃的水中,从而获得基于水性悬浮液的总重量计为约9%重量的固体含量。将获得的混合物混合约45分钟。
在50-55℃的温度下进一步混合浆料的同时,通过使用40%的CO2(+/-5%)和80min.-1的搅拌器速度(100%),以4500-5000Nm3/h开始碳酸化。浆料的温度由于放热反应的原因而在反应过程中得到提高。反应在电导率增加之后停止,在搅拌下加入2.0%的Na2SO4(d/d PHM-a)并混合15分钟,然后从容器中取出浆料。
所获得的浆料(浆料PHM-a)具有基于浆料的总重量计为16.5%重量的固体含量和81mPa·s的Brookfield粘度。
沉淀(或合成)水菱镁矿PHM-a的特性总结在下表1中。
表1
3、无均化的粒料的制备(参考)
粒料PHM1
PHM-a的浆料通过使用丹麦GEA-Niro的旋转雾化器通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体而被干燥。
用于喷雾干燥的设置在下表2中给出。
表2:
所获得的粒料PHM1的结果在表11中给出。
4、使用均化的粒料的制备(本发明)
粒料PHM2
沉淀(或合成)水菱镁矿(PHM-a)的浆料在Siegmund Linder的25L立式搅拌介质磨机中研磨,该磨机含有15kg ER102B 0.7/1.4mm(SEPR公司),进料流量为190L/h,尖端速度为5.3m/s,比能为约29kWh/t。
所获得的浆料(浆料PHM2)所具有的固体含量基于浆料的总重量计为17.3%重量。
在研磨后,沉淀(或合成)水菱镁矿具有下表3所示的特性。
表3:
d98(vol)[μm] | d50(vol)[μm] | BET比表面积[m2/g] |
50 | 6.75 | 44.3 |
然后通过使用丹麦GEA-Niro的双流体喷嘴通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体来干燥所获得的浆料(浆料PHM2)。
用于喷雾干燥的设置在下表4中给出。
表4:
所获得的粒料PHM2的结果在表11中给出。
粒料PHM3
在500巴的压力、50-70℃的温度和400L/h的进料流量下,在关闭的螺杆位置和小喷嘴下,将500L沉淀(或合成)水菱镁矿(PHM-a)的浆料一次泵送通过GEA MechanicalEquipment Italia S.p.A.的GEA Ariete NS3055均化器。
所获得的浆料(浆料PHM3)所具有的固体含量基于浆料的总重量计为17.6%重量。
在均化后,沉淀(或合成)水菱镁矿具有下表5所示的特性。
表5:
然后通过使用丹麦GEA-Niro的旋转雾化器通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体来干燥所获得的浆料(浆料PHM3)。
用于喷雾干燥的设置在下表6中给出。
表6:
所获得的粒料PHM3的结果在表11中给出。
粒料PHM4
在500巴的压力、50-70℃的温度和400L/h的进料流量下,在关闭的螺杆位置和小喷嘴下,将500L沉淀(或合成)水菱镁矿(PHM-a)的浆料一次泵送通过GEA MechanicalEquipment Italia S.p.A.的GEA Ariete NS3055均化器。
所获得的浆料(浆料PHM4)所具有的固体含量基于浆料的总重量计为17.6%重量。
在均化后,沉淀(或合成)水菱镁矿具有下表7所示的特性。
表7:
然后通过使用丹麦GEA-Niro的双流体喷嘴通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体来干燥所获得的浆料(浆料PHM4)。
用于喷雾干燥的设置在下表8中给出。
表8:
所获得的粒料PHM4的结果在表11中给出。
粒料PHM5
在500巴的压力、50-70℃的温度和400L/h的进料流量下,在关闭的螺杆位置和小喷嘴下,将500L沉淀(或合成)水菱镁矿(PHM-a)的浆料两次泵送通过GEA MechanicalEquipment Italia S.p.A.的GEA Ariete NS3055均化器。
所获得的浆料(浆料PHM5)所具有的固体含量基于浆料的总重量计为17.6%重量。
在均化后,沉淀(或合成)水菱镁矿具有下表9所示的特性。
表9:
然后通过使用丹麦GEA-Niro的双流体喷嘴通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体来干燥所获得的浆料(浆料PHM5)。
用于喷雾干燥的设置在下表10中给出。
表10:
所得粒料PHM5的结果也在下表11中给出。
表11:
下表12总结了对于(0.5巴)vs.(0.1巴)和(1.5巴)vs.(0.1巴)来说的比率d50和d10所确定的粒料稳定性。
表12:
从表12可以看出,通过包括均化包含含镁离子材料的水性悬浮液的步骤的方法所制备的粒料(即粒料PHM2、粒料PHM3、粒料PHM4和粒料PHM5)与通过相同方法但缺少均化包含含镁离子材料的水性悬浮液的步骤所获得的粒料(即粒料PHM1)相比更为稳定。要指出,作为均化步骤研磨后的样品在物理数据(脆性/堆密度)方面可能稍差,但它们在性能上是等同的。此外,图1-图5显示了通过现有技术方法制备的粒料(即粒料PHM1)对比通过本发明方法制备的粒料(即粒料PHM2、粒料PHM3、粒料PHM4和粒料PHM5)的SEM结果的对比。
进一步分析通过现有技术方法制备的粒料(即粒料PHM1)以及通过本发明方法制备的粒料(即粒料PHM2、粒料PHM3、粒料PHM4和粒料PHM5)的吸油能力。结果如下表13所示。
表13:
材料 | 装置 | 吸油率[%] |
粒料PHM1 | 旋转雾化器 | 80 |
粒料PHM2 | 双流体喷嘴 | 91.5 |
粒料PHM3 | 旋转雾化器 | n.d. |
粒料PHM4 | 双流体喷嘴 | 85.4 |
粒料PHM5 | 双流体喷嘴 | 91.4 |
n.d.:未测
粒料PHM6
PHM-b由包含沉淀(或合成)水菱镁矿的浆料(浆料PHM-b)获得,该浆料具有基于浆料的总重量计为15.5%重量的固体含量和40mPa·s的Brookfield粘度。
沉淀(或合成)水菱镁矿PHM-b的特性总结在下表14中。
表14
沉淀(或合成)水菱镁矿(PHM-b)的浆料在Siegmund Linder的25L立式搅拌介质磨机中研磨,该磨机含有15kg ER102B 0.7/1.4mm(SEPR公司),进料流量为190L/h,尖端速度为5.3m/s,比能为约33kWh/t。就在均化之前,将羧甲基纤维素(作为10%的溶液)以基于沉淀(或合成)水菱镁矿的总干重计为0.5%重量的量添加到浆料中。
所获得的浆料(浆料PHM6)所具有的固体含量基于浆料的总重量计为15.9%重量。
在均化后,沉淀(或合成)水菱镁矿具有在下表15中给出的特性。
表15:
然后通过使用丹麦GEA-Niro的旋转雾化器通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体来干燥所获得的浆料(浆料PHM6)。
用于喷雾干燥的设置在下表16中给出。
表16:
所获得的粒料PHM6的结果在表19中给出。
粒料PHM7
沉淀(或合成)水菱镁矿(PHM-b)的浆料在Siegmund Linder的25L立式搅拌介质磨机中研磨,该磨机含有15kg ER102B 0.7/1.4mm(SEPR公司),进料流量为190L/h,尖端速度为5.3m/s,比能为约33kWh/t。就在均化之前,将羧甲基纤维素以基于沉淀(或合成)水菱镁矿的总干重计为1.0%重量的量添加到包含沉淀(或合成)水菱镁矿的浆料(浆料PHM-b)中。
所获得的浆料(浆料PHM7)所具有的固体含量基于浆料的总重量计为15.6%重量。
在均化后,沉淀(或合成)水菱镁矿具有在下表17中给出的特性。
表17:
然后通过使用丹麦GEA-Niro的旋转雾化器通过喷雾干燥从包含沉淀(或合成)水菱镁矿的浆料中去除液体来干燥所获得的浆料(浆料PHM7)。
用于喷雾干燥的设置在下表18中给出。
表18:
所获得的粒料PHM7的结果在表19中给出。
表19:
下表20总结了对于(0.5巴)vs.(0.1巴)和(1.5巴)vs.(0.1巴)来说的比率d50和d10所确定的粒料稳定性。
表20:
从表20可以看出,通过包括均化包含含镁离子材料并且进一步包含羧甲基纤维素的水性悬浮液的步骤的方法所制备的粒料(即粒料PHM6和粒料PHM7)与通过相同方法但缺少均化包含含镁离子材料和羧甲基纤维素的水性悬浮液的步骤所获得的粒料(即粒料PHM1)相比更为稳定。
进一步分析粒料PHM6和粒料PHM7的吸油能力。结果在下表21中所示。
表21:
/>
Claims (16)
1.生产包含含镁离子材料的粒料的方法,该方法包括以下步骤:
a)提供包含含镁离子材料的水性悬浮液;
b)均化步骤a)的包含含镁离子材料的水性悬浮液,以及
c)借助于喷雾干燥从步骤b)的包含含镁离子材料的水性悬浮液中去除液体,以用于获得包含含镁离子材料的粒料。
2.根据权利要求1所述的方法,其中步骤a)的含镁离子材料选自含氢氧化镁材料、含碳酸镁材料、含氧化镁材料及其混合物,优选地,步骤a)的含镁离子材料是含碳酸镁材料,选自白云石(CaMg(CO3)2)、无水碳酸镁或菱镁矿(MgCO3),水菱镁矿(Mg5(CO3)4(OH)2·4H2O),纤菱镁矿(Mg2(CO3)(OH)2·3H2O),球碳镁石(Mg5(CO3)4(OH)2·5H2O),异水菱镁矿(Mg5(CO3)4(OH)2·5H2O),镁白孔雀石(Mg2(CO3)(OH)2·0.5H2O),水碳镁石(MgCO3·2H2O),多水菱镁矿(MgCO3·5H2O),白云质碳酸盐和三水菱镁矿(MgCO3·3H2O),更优选地,步骤a)的含镁离子材料是水菱镁矿,例如天然或合成水菱镁矿。
3.根据权利要求1或2所述的方法,其中步骤a)的含镁离子材料是经表面反应的含碳酸镁材料,其通过用一种或多种化合物处理含碳酸镁材料的表面而获得,所述化合物选自硫酸、磷酸、碳酸、含有至多六个碳原子的羧酸,优选选自甲酸、乙酸、丙酸、乳酸及其混合物;以及二羧酸和三羧酸,其中羧酸基团通过0-4个间断碳原子的链连接,优选选自草酸、柠檬酸、琥珀酸、马来酸、丙二酸、酒石酸、己二酸、富马酸及其混合物,或者其相应的盐。
4.根据权利要求1-3中任一项所述的方法,其中步骤a)的含镁离子材料具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
5.根据权利要求1-4中任一项所述的方法,其中步骤a)的水性悬浮液具有基于该水性悬浮液的总重量计为1-40%重量、优选5-35%重量、最优选7-26%重量的固体含量。
6.根据权利要求1-5中任一项所述的方法,其中在步骤b)之前和/或期间和/或之后添加至少一种崩解剂,优选地,该至少一种崩解剂选自交联羧甲基纤维素钠、改性纤维素胶、不溶性交联聚乙烯吡咯烷酮、淀粉、改性淀粉、淀粉羟乙酸盐如淀粉羟乙酸钠、微晶纤维素、预糊化淀粉、羧甲基淀粉钠、低取代羟丙基纤维素、N-乙烯基-2-吡咯烷酮的均聚物、烷基纤维素酯、羟烷基纤维素酯、羧基烷基纤维素酯、藻酸、微晶纤维素及其多晶型、离子交换树脂、树胶、甲壳素、壳聚糖、粘土、结冷胶、交联泼拉克林共聚物、琼脂、明胶、糊精、丙烯酸聚合物、羧甲基纤维素钠/钙、邻苯二甲酸羟丙基甲基纤维素、虫胶、泡腾混合物如碳酸氢盐组合一种或多种酸如柠檬酸或酒石酸、或其混合物。
7.根据权利要求6所述的方法,其中该至少一种崩解剂在步骤b)之前和/或期间和/或之后以0.1-10%重量、优选0.3-10%重量、更优选0.5-8%重量、最优选1-约5%重量的量添加,基于该含镁离子材料的总干重计。
8.根据权利要求1-7中任一项所述的方法,其中步骤b)中的均化进行一次或多次,优选1-5次,更优选1-3次。
9.根据权利要求1-8中任一项所述的方法,其中步骤b)中的均化通过研磨进行。
10.根据权利要求1-8中任一项所述的方法,其中步骤b)中的均化在以下条件下进行:
a)50-900巴、优选100-750巴、最优选130-650巴的压力,和/或
b)5-95℃、优选10-80℃、最优选15-60℃的初始温度。
11.根据权利要求1-10中任一项所述的方法,其中步骤c)中的喷雾干燥在以下条件下进行:
a)0.1-300巴、优选1-100巴、更优选1至<50巴、最优选1-25巴的进料压力,和/或
b)120-950℃、优选175-700℃、最优选180-550℃作为入口温度测量的温度。
12.包含含镁离子材料的粒料,其中该粒料具有的堆密度为0.10-0.70g/mL,优选0.12-0.65g/mL,更优选0.20-0.60g/mL,最优选0.15-0.50g/mL。
13.根据权利要求12所述的粒料,其中该粒料具有
a)体积粒子尺寸d90为15-500μm,优选20-400μm,最优选30-250μm,通过激光衍射在0.1巴分散压力下干燥测量,和
b)体积中值粒子尺寸d50为5-300μm,优选8-200μm,最优选10-150μm,通过激光衍射在0.1巴分散压力下干燥测量,和
c)体积粒子尺寸d10为1-100μm,优选2-70μm,最优选4-50μm,通过激光衍射在0.1巴分散压力下干燥测量,和/或
d)BET比表面积为20-90m2/g,优选30-80m2/g,最优选40-70m2/g,根据ISO 9277:2010使用氮气和BET法测量,和/或
e)球形。
14.根据权利要求12或13所述的粒料,其中该粒料包含含镁离子材料的粒子,该含镁离子材料的粒子具有
a)体积中值粒子尺寸d50为1-75μm,优选1.2-50μm,更优选1.5-30μm,甚至更优选1.7-15μm,最优选1.9-10μm,通过激光衍射确定,和/或
b)体积顶切粒子尺寸d98为2-150μm,优选4-100μm,更优选6-80μm,甚至更优选8-60μm,最优选10-40μm,通过激光衍射确定;和/或
c)BET比表面积为10-100m2/g,优选12-70m2/g,最优选17-60m2/g,根据ISO 9277:2010使用氮气和BET法测量;和/或
d)粒子内侵入式比孔容为0.9-2.3cm3/g,优选1.2-2.1cm3/g,最优选1.5-2.0cm3/g,由汞孔隙率测定法测量结果计算。
15.根据权利要求12-14中任一项所述的粒料,其中该粒料通过根据权利要求1-11中任一项所述的方法获得。
16.根据权利要求12-15所述的粒料在营养产品、农业产品、兽医产品、化妆产品中、优选在干化妆品和/或干皮肤护理组合物中、在家用产品、食物产品、包装产品、个人护理产品中、优选在口腔护理组合物中、在空气处理和水处理中、或者在药物产品中作为赋形剂的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21193840.2 | 2021-08-30 | ||
EP21193840.2A EP4140953A1 (en) | 2021-08-30 | 2021-08-30 | Method for the production of granules comprising a magnesium ion-comprising material |
PCT/EP2022/074131 WO2023031230A1 (en) | 2021-08-30 | 2022-08-30 | Method for the production of granules comprising a magnesium ion-comprising material |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117794861A true CN117794861A (zh) | 2024-03-29 |
Family
ID=77543419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280053423.2A Pending CN117794861A (zh) | 2021-08-30 | 2022-08-30 | 生产包含含镁离子材料的粒料的方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4140953A1 (zh) |
CN (1) | CN117794861A (zh) |
WO (1) | WO2023031230A1 (zh) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB594262A (en) | 1945-06-14 | 1947-11-06 | Basic Refractories Inc | Improved process for the treatment of magnesian materials |
US935418A (en) | 1907-10-28 | 1909-09-28 | George Sisson | Method of producing magnesium carbonate. |
US1361324A (en) | 1918-03-18 | 1920-12-07 | Nat Magnesia Mfg Company | Process of manufacturing magnesium carbonate |
GB544907A (en) | 1941-02-24 | 1942-05-01 | Ocean Salts Products Ltd | Improvements relating to the production of magnesium basic carbonate, or magnesia |
GB548197A (en) | 1941-02-24 | 1942-09-30 | Ocean Salts Products Ltd | Producing high quality magnesium compounds from magnesium-containing substances |
US4985459A (en) | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US5230734A (en) | 1991-07-29 | 1993-07-27 | Okutama Kogyo Co., Ltd. | Calcium-magnesium carbonate composite and method for the preparation thereof |
US5979461A (en) | 1997-03-24 | 1999-11-09 | Philip Morris Inc. | Smoking article wrapper having filler of hydromagnesite/magnesium hydroxide and smoking article made with said wrapper |
US6582738B2 (en) | 1999-09-13 | 2003-06-24 | Deseret Laboratories, Inc. | Process for preparing chewing gum containing a nutritional supplement |
US20030157213A1 (en) | 2002-02-19 | 2003-08-21 | Jeffrey Jenkins | Nutrient chewing gum |
AU2005227634A1 (en) | 2004-03-23 | 2005-10-13 | Imerys Pigments, Inc. | Effective reductive bleaching of mineral slurries |
JP4944466B2 (ja) * | 2006-03-22 | 2012-05-30 | 宇部マテリアルズ株式会社 | 無水炭酸マグネシウム粉末及びその製造方法 |
BE1020577A3 (fr) | 2012-03-22 | 2014-01-07 | Lhoist Rech & Dev Sa | Composition minerale a base d'une phase solide mixte de carbonates de calcium et de magnesium, son procede de preparation et son utilisation. |
BE1021832B1 (fr) | 2013-09-19 | 2016-01-21 | S.A. Lhoist Recherche Et Developpement | Composition minerale a base d'une phase solide mixte de carbonates de calcium et de magnesium et procede de preparation d'une telle composition |
EP3517502A1 (en) | 2018-01-26 | 2019-07-31 | Omya International AG | Carrier material for the release of one or more active agent(s) in a home care formulation |
EP3733154A1 (en) * | 2019-05-03 | 2020-11-04 | Omya International AG | Magnesium ion-containing materials as white pigments in oral care compositions |
EP3733785A1 (en) | 2019-05-03 | 2020-11-04 | Omya International AG | Surface-reacted magnesium carbonate as carrier material for the release of one or more active agent(s) in a home care formulation |
-
2021
- 2021-08-30 EP EP21193840.2A patent/EP4140953A1/en not_active Withdrawn
-
2022
- 2022-08-30 CN CN202280053423.2A patent/CN117794861A/zh active Pending
- 2022-08-30 WO PCT/EP2022/074131 patent/WO2023031230A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023031230A1 (en) | 2023-03-09 |
EP4140953A1 (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7014786B2 (ja) | 投与製剤の製造方法 | |
CN108291096B (zh) | 用于生产包含经表面反应的碳酸钙的粒料的方法 | |
JP7014787B2 (ja) | 投与製剤の製造方法 | |
US20230174786A1 (en) | Method for the production of free-flowing granules | |
US20230181468A1 (en) | Granules comprising surface-reacted calcium carbonate as excipient | |
CN117794861A (zh) | 生产包含含镁离子材料的粒料的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |